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ABSTRACT
Class II Major Histocompatibility Complex (MHCII) molecules are transmembrane 
glycoproteins expressed on the surface of antigen-presenting cells (APCs). APCs engulf 
pathogens and digest pathogenic proteins into peptides, which are loaded onto MHCII in the 
MHCII compartment (MIIC) to form peptide-MHCII complexes (pMHCII). These pMHCII are 
then presented to CD4+ T cells on the surface of APCs to trigger an antigen-specific immune 
response against the pathogens. HLA-DM (DM), a non-classical MHCII molecule, plays an 
essential role in generating kinetically stable pMHCII complexes which are presented to CD4+ T 
cells. When a few peptides among the pool of the peptide repertoire can generate the efficient 
CD4+ T cell response, such peptides are known as immunodominant. The selection of 
immunodominant epitopes is essential to generate effective vaccines against pathogens. The 
mechanism behind immunodominant epitope selection is not clearly understood. My work is 
focused on investigating various factors that help in the selection of immunodominant epitopes. 
For this purpose, peptides derived from H1N1 influenza hemagglutinin protein with known 
CD4+ T cell responses have been used. We investigated the role of DM-associated binding 
affinity in the selection of immunodominant epitopes. Our analysis showed that the presence of 
DM significantly reduces the binding affinity of the peptides with low CD4+ T cell response and 
inclusion of DM-associated IC50 in training MHCII algorithms may improve the binding 
prediction. Previous studies have shown that there is an alternate antigen presentation depending 
on antigen protein properties. Here, we showed that the immunodominant epitope presentation is 
dependent on the pH and length of the peptides. To study the MHCII in its native form, we 
assembled full-length MHCII in a known synthetic membrane model known as nanodiscs. We 
noted that, based on the lipid composition, assembly of the MHCII differs. Preliminary binding 
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studies with this tool showed that there might be a difference in the binding based on the type of 
the nanodisc. Collectively, our results showed that the immunodominant epitope selection is a 
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An introduction to the immune system
The Immune system is a complex system comprised of different branches with the primary 
function of protecting us from foreign pathogens and the potentially harmful effect of host 
invasion. When an organism encounters a pathogen, the immune system is activated and 
generates a response that tailors to the nature of the antigen. The Immune system could be 
divided broadly into two parts: Innate immunity and adaptive immunity. Innate immunity 
generates an immune response targeting primary infection and inflammation and acts as the first 
line of defense in the immune system (Bonilla & Oettgen, 2010). Studies have also shown that 
innate immunity is altered during sepsis, which makes hosts susceptible to secondary infections 
(Delano et al., 2011). Innate immunity does not have a memory, and with repeated encounters to 
the same pathogen, it generates comparable responses, and the same processes are triggered as 
soon as the infection occurs. Instead, adaptive immunity is developed over time, is specific for 
the antigen and modified upon repeated encounters, and finally establishes a long-lasting 
memory. Adaptive immunity involves crosstalk between antigen-presenting cells (APCs), T- 
cells, and B-cells.
Cells and molecules of the immune system
The immune system is made up of many cells and proteins, which helps in generating an immune 
response. All cell types originate from stem cells and classified into two main classes: Lymphoid 
stem cells (Lymphocytes) and myeloid stem cells (Granulocytes). Lymphocytes are further 
classified into three types: B-cells, T-cells, and Natural killer cells. Granulocytes are classified into 
macrophages, dendritic cells, neutrophil, eosinophil, basophil, and mast cells. Granulocytes cells, 
specialized in phagocytosis, engulf the whole pathogen and destroy them using digestive enzymes. 
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On the other hand, lymphocytes have more specialized roles. Natural killer cells induce apoptosis 
of infected cells. B-cells originate and mature in the bone marrow and express antibodies against 
specific antigens as well as present antigens to T-cells. T-cells are generated in bone marrow yet 
mature in the thymus. T-cells express unique receptors (T-cell receptors or TCR) on their surface 
along with CD (cluster of differentiation) glycoproteins. TCR is specific for the recognition of 
MHC bound antigen. T-cells are classified into two types based on CD glycoproteins: CD4+ T 
cells (helper T cells) - which recognize MHCII proteins and CD8+ T cells (Cytotoxic T cells) - 
which recognize MHCI proteins (Meuer et al., 1983). T cells generate an immune response by 
secreting cytokines, which are responsible for the differentiation of monocytes, macrophages. 
They are also responsible for the maturation of B-cells, antibody production, and activation of 
phagocytic cells.
Apart from immune cells, different types of immune proteins play an essential role in the regulation 
of immune response. The primary immune proteins are antibodies, cytokines, complement 
proteins, CD receptors, and MHC proteins. Antibodies are present on B-cells, which help in 
defense against bacteria and viruses, also develop memory against the pathogens. Cytokines are 
secreting proteins that act as a messenger to stimulate different cells and keep a check on the 
immune system. Complement proteins are a set of proteins that help in destroying pathogens by 
activating a set of cascade reactions. There are many CD molecules present in the immune system 
with a variety of functions. One of the functions of CD receptors are to act as cell surface receptors 
and help in antigen recognition. The list of the proteins mentioned here is by far not comprehensive 
considering the plethora of the proteins required for proper immune function. This thesis revolves 
around Major histocompatibility complex (MHC), a family of transmembrane glycoproteins 
present on the surface of APCs composed of MHCI, MHCII, and MHCIII. These MHC molecules 
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play a crucial role in the antigen presentation pathway. This thesis is focused on MHCII.
Overview of antigen presentation pathways
Antigen presentation is a process where the antigen is presented by antigen-presenting cells 
(APCs) to T-cells. There are two main antigen-presenting pathways - class I MHC and Class II 
MHC pathway (Neefjes, Jongsma, Paul, & Bakke, 2011). Class I MHC pathway is involved in 
presenting endogenous proteins. All nucleated cells express MHCI molecules and present 
proteins to CD8+ T cells. The proteins synthesized by a healthy cell are tolerated by CD8+ T 
cells. On the other hand, when a cell gets infected or undergoes mutations, the peptidome 
generated by them allows CD8+ T cells to detect them and help the immune system to destroy 
these infected or abnormal cells.
Class II MHC pathway present exogenous proteins (Figure 1.1). APCs express Class II MHC 
molecules (Hume, 1985). They take up the foreign pathogen, leading to the degradation of the 
pathogen proteins by the endosome. These protein fragments get presented to MHCII for 
binding. The selected peptide bound to MHCII gets transported to the surface of APCs, and it is 
here that these proteins are presented to CD4+ T cells. CD4+ T cells generate an immune 
response against this pathogen after the presentation of peptides generated from the pathogen.
3
Figure 1.1: Class II MHC pathway: Newly synthesized MHCII molecules are transported via 
invariant chain to MIIC, directly or via cell membrane, where cathepsin cleaves the invariant 
chain to a shorter peptide CLIP, which is removed by non-classical MHCII molecule DM. The 
empty peptide binding site exchanges various peptides derived from antigen protein in the 
presence of DM. The selected pMHCII complex gets transported to the cell surface for the 
activation of CD4+ T cells (Neefjes et al., 2011).
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MHC (Major histocompatibility class) gene
MHC gene is present on chromosome 6 in humans and represented as HLA (Human leukocyte 
antigen) (Stimpfling, 1971). There are three MHC genes: MHCI, MHCII, and MHCIII. For 
MHCI, there are three genes: HLA-A, HLA-B, and HLA-C. There are six genes for MHCII: 
HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRA, and HLA-DRB1, while not 
much is known for the MHCIII gene other than it is involved in inflammation and other immune 
functions.
Class I MHC or endogenous pathway
Regularly, healthy proteins are degraded by the proteasome in the cells which get cleared from 
the system without generating an immune response since CD8+ T cells have tolerated such 
proteins. T-cells learn to differentiate between self and non-self-proteins so that the immune 
system doesn't produce an immune response against its protein. However, in the case of a 
productive mutation, or if the cell becomes infected, the protein fragments generated by the 
proteasome is recognized by CD8+ T cells. Cytoplasmic protein-derived peptides produced by 
the proteasome are further trimmed or degraded by cytosolic peptidase. Some fragments escape 
to the endoplasmic reticulum (ER) via a transporter embedded in the ER membrane known as 
transporter associated with antigen processing (TAP) (Solheim, Carreno, & Hansen, 1997). In 
the ER, the peptide loading complex (PLC) selects these fragments and facilitates it's 
complexing to MHCI, for presentation to CD8+ T cells. The PLC is comprised of MHCI, 
ERp57, Calreticulin and tapasin. As the peptide-binding site of MHCI can accommodate 
peptides 8-10 amino acid long, the peptide transported via TAP might require further trimming 
by the ER aminopeptidase associated with antigen (ERAAP). In the ER, MHCI is partially 
folded and stabilized by calreticulin and ERp57 (Farmery, Allen, Allen, & Bulleid, 2000).
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Tapasin acts as a peptide editor and helps in accelerating the exchange of the peptides generated 
by ERAAP and transported by TAP. Once the PLC produces an efficient peptide-MHCI 
complex, this is carried to the cell surface to interact with CD8+ T cells (Solheim, 1999). 
Class II MHC or exogenous pathway
MHCII molecules present peptides that derive from extracellular proteins or self-proteins 
generated by the endosomal pathway, as shown in Figure 1.1. MHCII unit assembles in the ER 
along with the invariant chain, which shields the peptide binding site from peptides present in the 
ER and directs the trafficking of MHCII molecules to the MHCII compartment (MIIC). In MIIC, 
the invariant chain is cleaved, leaving only a smaller peptide fragment known as class II- 
associated invariant chain peptide (CLIP) bound to the groove. HLA-DM (DM), a non-classical 
MHCII molecule, removes the CLIP peptide and makes the peptide binding site accessible to 
peptides derived from extracellular fragments. DM also helps in accelerating the peptide 
exchange and in the selection of kinetically stable peptide-MHCII (pMHCII) complexes 
(Kropshofer et al., 1996). pMHCII complexes then are transported to the cell surface where they 
interact with CD4+ T cells.
The research presented here focuses on understanding various factors that are required for MHC 
II-restricted peptide selection.
Immunodominance
The phenomenon of immunodominance is associated with the T-cell response. For a protein 
antigen, T-cell response is specific to only a few of the panoply of peptides generated by 
endosomal digestion. These peptides responsible for driving the antigen-specific T-cell responses 
are known as immunodominant. Immunodominance is found in class I and class II MHC, but it 
is mostly studied in MHCII. The need for immunodominant epitope is due to the limited space of 
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memory cells in lymph nodes (Berkower, Kawamura, Matis, & Berzofsky, 1985). So, to reduce 
the number of memory cells for the same antigen, only a few epitopes from that antigen generate 
a T-cell specific response.
Immunodominant epitope selection is a complex process that depends on various factors, such as 
peptide affinity for MHCII, susceptibility to specific proteases, structural features of antigens, 
and T cell receptor affinity for pMHCII complexes. There are currently two main hypotheses for 
immunodominant epitope selection: 1. epitope accessibility, and 2. kinetic stability (Kim & 
Sadegh-Nasseri, 2015).
Epitope accessibility presumes that immunodominant epitopes must be accessible to MHC 
binding sites or cathepsins cleavage. The support for this theory comes from the studies which 
have shown that the position of many known immunodominant epitope is near C- or N- termini 
of the protein or its flexible strands (Dai, Steede, & Landry, 2001). Instead, the kinetic stability 
model defines immunodominant epitopes based on their ability to form stable complexes with 
MHCII. Support for this model comes from the studies which show that high-affinity complexes 
show DM resistance (Lazarski et al., 2005).
Structural characteristics of MHC
MHCI and MHCII proteins are quite similar in structure. They have a membrane-proximal 
immunoglobulin-like domain and a membrane distal peptide binding site which comprises of 
eight-stranded beta-sheet and two-alpha helical region. The polymorphism mostly resides in the 
binding site. The significant difference in the structure is at the peptide-binding region, in that 
MHCI has a closed-groove peptide binding site that can accommodate a peptide residue of 8-10 
amino acid long (Wilson & Fremont, 1993), while MHCII has an open-groove binding site due 
to which the peptide length is not restricted. The primary reason for differences in the epitope 
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mapping between MHCI and MHCII is due to their peptide-binding site. As MHCI has a 
limitation on amino-acid residues binding to the pockets lining the groove, it is relatively easier 
to map binding-motifs specific to different alleles while this is more difficult in the case of 
MHCII, as the alignment of amino-acid residues for longer peptides creates more probability of 
side-chain positioning to each binding pocket (Chaves, Lee, Nayak, Richards, & Sant, 2012). 
The first crystal structure of MHCII (HLA-DR1 allele) with HA306-318 shows that peptide binds 
in a polyproline helix conformation. The peptide binds as an extended straight strand where N 
and C termini projected out of the binding pocket. In the MHCII binding site, various pockets are 
numbered as P1 to P10. These pockets refer to the position of the amino-acid chain of the peptide 
which will reside in that specific pocket. The lining of these pockets is highly polymorphic, 
causing the allele dependent peptide specificity. P1, P4, P6, P7, and P9 accommodate the side 
chain of the peptide which are crucial in determining the interaction between MHCII and 
peptide, as shown in Figure 1.2. The P1 pocket is the deepest pocket that accommodates mainly 
hydrophobic side chains near the peptide N terminus. Peptide binding to MHCII relies primarily 
on the H-bond network and hydrophobic interactions. H-bond network is established between the 
main chain of the peptide to the central and conserved side chain residues of MHCII, as shown in 
Figure 1.3. The alpha-chain residues which are involved in H-bond is α-53, α-9, α-62, α-69 and 
α-76. The beta-chain residues are β-81, β-82, β71, β-62, and β-57 (Painter & Stern, 2012).
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Figure 1.2: The major pocket P1, P4, P6, P7 and P9 in HLA-DR1, which plays crucial role in 
peptide interaction with MHCII (Stern et al., 1994).
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Figure 1.3: Hydrogen bond network between peptide HA306-318 and MHCII binding site. Peptide 
is shown as stick representation. Bottom figure shows chemical diagram, with conserved residue 
of MHCII which contribute to H-bonding, with position of peptide side chain mentioned in red 
(Painter & Stern, 2012).
HLA-DM : non-classical MHCII molecule
DM is a non-classical MHCII molecule which itself does not present epitopes but contributes to 
the selection of the peptides, which presents to CD4+ T cells. A newly synthesized MHCII 
molecule binding site is covered by the invariant chain, which helps in the transportation of 
MHCII to MIIC and shields the peptide binding site from the endogenous peptides. In MIIC, 
invariant chain is cleaved to a shorted peptide known as CLIP. DM removes the CLIP peptide 
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from the binding site and enables the binding of the antigenic peptide to MHCII (Kropshofer et 
al., 1996; Stebbins, Peterson, Suh, & Sant, 1996). Studies have shown that DM also accelerates 
the exchange of peptides and helps in the selection of kinetically stable pMHCII complexes. The 
mechanism behind DM action is still poorly understood. Various studies are proposing different 
mechanisms via which DM helps in the selection of immunodominant epitopes. Studies have 
shown that the rate of peptide exchange is directly proportional to intrinsic dissociation rate of 
pMHCII complexes (Weber, Evavold, & Jensen, 1996). These studies supported the kinetic 
stability model of immunodominant selection. DM role is not only limited to accelerating the 
exchange of the peptides, but it has also shown that DM can act as MHCII-chaperone and 
stabilize the empty MHCII at low pH (Denzin, Hammond, & Cresswell, 1996; Kropshofer, 
Arndt, Moldenhauer, Hammerling, & Vogt, 1997). To further understand the DM mechanism of 
action, the crystal structure of DM along with DR1-HA complex molecule was solved. Pos et al. 
manipulated the N terminal site near P1 pocket to achieve this complex, as DM does not bind to 
DR1 when binding site occupies by covalently linked peptide (Pos et al., 2012). As P1 pocket 
plays an important for HA binding to DR. The structure showed that αW43 residue of the P1 
pocket of DR1 plays a vital role in DM binding. This residue stabilizes the P1 pocket in the 
DR1-HA complex, but in DM-DR1-HA complex it is rotated away from P1 pocket. The indole 
ring of αW43 forms an H-bond with DM αN125. Mutation of αN125 to alanine completely 
abolishes the DM activity. So, based on this observation, the model they proposed for DM 
activity is that occlusion of P1 pocket by high-affinity peptides makes them resistant to DM 
activity (Pos et al., 2012).
Another model that is widely accepted is that DM activity is dependent on the conformation of 
the MHCII. It has shown that low-affinity peptides form a less rigid complex with MHCII, which
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makes them DM susceptible. There is a specific region that is involved in MHCII conformational 
change. One study showed that substitution of αF54C in the DR1 molecule makes it sensitive to 
DM activity as compared to wild-type DR1, even when a high-affinity peptide is bound. The 
structure revealed a reorientation in the α45-50 region and changes in the flanking extended 
region α39-44 and α51-54. These regions are involved in DM interaction (Painter et al., 2011). 
DM activity is also dependent on MHCII polymorphism. It has been shown that there are alleles 
that feature DM-independent antigen presentation. One such type allele is DQ, and it can easily 
attain SDS stable conformation with Ii alone while DR alleles stability depends on Ii as well as 
DM.
Apart from dependence on MHCII allele specificity and structural conformation, another 
essential factor that drives DM activity is pH. Indeed, DM activity is optimum at pH 4.5 - 5.5 
and reduces at neutral pH. The effect of pH on DM activity is related to the protonation of the 
proteins. The non-polar region of DR and DM plays a vital role in their interaction. In acidic 
conditions, the non-polar patch on both the proteins are usually exposed as compared to neutral 
pH. CD and fluorescence spectra have also shown that DM structure is different at pH 5 and 7. 
The work presented here investigates biochemical and biophysical factors that can impact DM 
function.
Forces responsible for peptide binding to MHCII
Significant efforts have been put forth to identify the biochemical and biophysical features of a 
pMHCII complex that makes it immunodominant. Historically, the two main biochemical 
characteristics that have been studied are binding affinity and kinetic stability. One report has 
extensively studied all the biochemical features associated with pMHCII for epitope selection. 
They studied IC50 (binding affinity), intrinsic dissociation half-life, and DM-mediated 
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dissociation half-life for peptides derived from the vaccinia virus with known DR1 epitopes. 
They showed that DM-associated half-life is an essential factor in selecting immunogenic 
epitope (Yin, Calvo-Calle, Dominguez-Amorocho, & Stern, 2012). There are other reports which 
showed a direct correlation between peptide intrinsic half-life and immunogenicity, stating 
immunodominant peptide having half-lives >150 hrs and cryptic peptide with less than 10 hrs 
(Lazarski et al., 2005). Another important feature that contributes to epitope selection is peptide 
binding to MHCII. Peptide binding to MHCII fundamentally involves encapsulation of the 
hydrophobic side chain in polymorphic pockets lining the binding site, and the establishment of 
an extensive H-bond network between side chains of non-polymorphic MHC residues and the 
backbone of the peptide. There are nine major positions in the binding site of MHCII, indicated 
with P1 through P9. The major pockets that are involved in the peptide interaction are P1, P4, 
P6, P7, and P9 (Stern et al., 1994). Particularly for DR alleles, and for other class II human and 
murine MHCII, the binding specificity of P1 to P9 positions have been extensively studied. The 
P1 pocket as mentioned above plays a vital role in stable peptide binding as well as in DM 
activity. This is the most hydrophobic pocket and prefers accepting large hydrophobic side 
chains (Trp, Tyr, Phe, Leu, and Ile). P4, P6, P7 are shallower pockets. P4 binds to large aliphatic 
side chains, P6 preferred smaller residues like Threonine. P9 is the deep pocket on the C-term 
side of the complex and prefers hydrophobic residues. One report has shown that the P10 
positions can significantly contribute to binding on a residue-by-residue and peptide-by-peptide 
basis (Zavala-Ruiz, Strug, Anderson, Gorski, & Stern, 2004). Another rarely studied biochemical 
feature of pMHCII complex is its thermodynamic feature. Ferrante et al showed a correlation 
between structural and entropic component of pMHCII complexes. They have shown that 
flexible complexes with greater entropic penalty shows susceptibility to DM action (Ferrante,
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Templeton, Hoffman, & Castellini, 2015). Thus, biochemical and biophysical characteristics of 
pMHCII complexes play a significant role in the selection of immunodominant epitope as 
determined by their DM susceptibility.
Immunodominant epitope prediction
MHCII presentation pathway generates a peptide repertoire for a pathogen, among which only a 
few determine the CD4+ T cell response against that pathogen. Those peptides are 
immunodominant epitopes. Engineering peptide-based vaccines require the knowledge of the 
pathogen-specific immunodominant epitopes, which can be used in lieu of the full pathogen or 
relevant recombinant antigens to induce a cellular and humoral memory. Indeed, the standard 
approach for epitope discovery involves isolation of pathogenic protein, constructing its protein 
and its fragments, measuring its binding affinity, or testing with CD4+ T cells to regulate the 
immune response. This approach is evidently time- and labor-intensive. To overcome the 
limitations of the classical epitope discovery approach, various epitope predictive algorithms 
have been generated (Bian, 2003; Nielsen, Lund, Buus, & Lundegaard, 2010; Nielsen et al., 
2008; Nielsen, Lundegaard, & Lund, 2007). These algorithms are trained based on a database 
collecting experimentally validated epitopes. They used different computational training methods 
such as neural networks, multivariate statistical analysis, and consensus (Bisset & Fierz, 1993;
Burden & Winkler, 2005). The prediction considers peptide binding affinity fundamentally to 
MHCII as a proxy for immunogenicity. The crystal structure of pMHCII has shown that the 
primary force of binding is peptide side chain binding to major pockets of MHCII; the 
algorithms investigate the amino-acid interaction which can fit into these pockets. The training 
dataset helps in refining this prediction, and the algorithm predicts the 9-core amino-acid which 
will fit in the binding site. This approach is useful for class I, but for class II this approach has 
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various limitations. One major limitation is due to the difference in the binding groove of these 
two molecules. Class I has a close groove while class II has an open groove; thus, it can bind 
peptides varying in length from 9-25 amino acids. For longer peptides, identifying the amino 
acids driving MHCII binding and those causing T-cell recognition is not known. Studies have 
also shown that the flanking residues also play an essential role in CD4+ T cell interaction 
(Holland, Cole, & Godkin, 2013). Hence, the epitope for class II alone is not enough to train the 
algorithm. The training dataset is generally only focused on the binding dataset or limited 
available CD4+ T cell data. The presentation of the epitope is such a complex process that 
involves several factors such as DM activity, cathepsin activity, CD4+ T cell interaction points, 
and allele dependence. Thus, training algorithms based only on binding datasets and limited 
epitope data is not enough. It is essential to consider all factors to generate efficient algorithms. 
Significance of MHCII assembly in the membrane
MHCII are transmembrane glycoproteins which are assembled as a heterodimer in the 
membrane. MHCII molecule is comprised of α and β chain with membrane proximal, distal, and 
transmembrane portion (Stern et al., 1994). In the ER, a newly synthesized molecule transported 
as a nonameric complex along with an invariant chain as a chaperone to MIIC. MHCII molecule 
has also shown the tendency of dimerization of heterodimer (superdimers) in the soluble form. 
Its crystal structure has shown the dimer of αβ heterodimers arranged in parallel fashion, 
suggesting its tendency to dimerize associated with CD4+ T cell recognition (Brown et al., 2015; 
Cochran & Stern, 2000; Schafer, Malapati, Hanfelt, & Pierce, 1998). Studies supporting this 
hypothesis have shown that monomers are not stimulatory for T cells. Trimeric or tetrameric 
agonist ligand shows better TCR stimulation (Boniface et al., 1998). One study demonstrated 
that this dimer of dimers could stimulate CD4+ T cells for low-affinity antigens much better than 
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high-affinity antigens (Schafer & Pierce, 1994). The single-particle imaging study has also 
shown the presence of dimer of dimers in living cells, which are more prevalent at 22°C as 
compare to 37°C, showing its dependence on temperature and lipid environment (Cherry et al., 
1998). The empty MHCII has the inherent property to aggregate in the absence of peptide and 
binding of the peptide stabilize it against aggregation (Stern & Wiley, 1992). The arrangement of 
MHCII in the membrane and tendency of purified MHCII to aggregate as dimer of dimers 
suggest that the arrangement of MHCII plays an essential role in the stabilization of MHCII and 
its function. In the early and late '90s, these superdimers were studied extensively regarding their 
role in CD4+ T cell activation. How they will impact the binding of the antigen has not been 
well-studied. We attempted to study the assembly of MHCII in model membranes of various 
lipid compositions and assess whether these model membranes are suitable for peptide binding 
studies.
The big picture
MHCII antigen presentation required various factors to select immunodominant epitope for 
presentation to CD4+ T cells, which generate an efficient response against a specific pathogen. 
Our work focuses on investigating different factors that are involved in immunodominant epitope 
selection. DM role in the selection of immunodominant epitope is extensively studied from the 
kinetic stability of the pMHCII perspective, but we investigated its role from binding affinity 
point of view. The epitope predictive algorithms are focused on binding affinity data without 
DM and epitope identification through T cell analysis. We have shown that DM-associated 
binding affinity is a proxy for immunodominance and has better predictive property. Next, to 
understand the DM mechanism of action, we have studied the structural features of the pMHCII 
complex. We have also considered the impact of pH on the kinetic stability of pMHCII and its 
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association with DM activity. In the end, we incorporate a full-length MHCII protein in the 
synthetic membrane to study the impact of lipid composition on its assembly. Studying these 
various biochemical features provide us significant insight into the role of DM and assembly of
MHCII in the selection of immunodominant epitope.
Figure 1.4: The overview of the research work presented in this thesis
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Chapter 2: HLA-DM associated binding affinity as a proxy of immunodominance1
1 Osan, J.K, Kuhn T. B, Ferrante, A. (In Prep) HLA-DM associated binding affinity as a proxy of 
immunodominance. Journal of Immunology
Abstract
Binding of antigenic peptides to class II MHC molecules (MHCII) and the activity of the “editing” 
molecule HLA-DM (DM) on the resulting peptide-MHCII complexes are critical factors in the 
antigen presentation pathway. During processing, a panoply of antigen-derived peptides generated, 
of which only a few known as “immunodominant” are the focus of CD4+ T cell recognition. 
Different algorithms are available to predict the peptide-MHC binding and to identify CD4+ T cell 
epitopes within pathogenic proteins. Here we examined whether the inclusion of DM during 
peptide-MHCII binding events would facilitate identifying immunodominant epitopes. We used 
a competition binding assay to quantify the binding affinity of each peptide from a library of 
sequences covering the entire hemagglutinin protein from H1N1 influenza virus for which an 
HLA-DR1 restricted immunodominance hierarchy had been already established. Our data showed 
that the presence of DM significantly lowered the binding affinity of weaker epitopes but not that 
of immunodominant epitopes. Statistical analysis showed that DM-associated binding affinity of 
immunodominant was significantly different than weaker epitopes (P = 0.0028). Upon comparing 
binding affinity predicted by algorithms to the measured binding affinity, we observed that DM- 
associated binding affinity yields a better prediction. These findings indicate that DM-associated 




Class II major histocompatibility complex (MHCII) molecules are glycoproteins expressed on the 
surface of antigen-presenting cells (APCs) and present peptides derived from foreign pathogens to 
CD4+ T cells, leading to a T-dependent immune response (Neefjes, Jongsma, Paul, & Bakke, 
2011). APCs take up pathogens, or fragments thereof, through different mechanisms, and process 
them within endo-lysosomal compartments to be enzymatically cleaved into peptides. In one of 
these compartments named MHCII compartment (MIIC), peptides compete for binding to MHCII 
molecules. Peptide-MHCII complexes (pMHCII) are then shuttled to the plasma membrane for 
recognition by CD4+ T cells. The peptides, among the repertoire of peptides generated by 
endosomal digestion, which produce the most potent CD4+ T cell response, are known as 
immunodominant (Kim & Sadegh-Nasseri, 2015). Apart from the binding of MHCII to the 
peptide, another factor with a critical role in the selection of immunodominant peptides is HLA- 
DM (DM), a non-classical MHCII molecule which itself does not bind to peptides but helps in the 
selection of pMHCII for presentation to CD4+ T cells (Ferrante, Anderson, Klug, & Gorski, 2008). 
When a newly synthesized MHCII molecule is generated in the endoplasmic reticulum (ER), its 
peptide-binding site is occupied with the invariant chain, preventing the binding of other peptides 
present in the ER. When the MHCII molecule reaches the MIIC, cathepsins (such as cathepsin S) 
cleave the invariant chain leaving a smaller peptide known as Class II-associated invariant chain 
(CLIP) bound. DM first removes CLIP from the binding site of newly synthesized MHCII, 
enabling the binding of antigenic peptides to MHCII. Studies have shown that DM also accelerates 
the exchange of peptides and generates stable pMHCII, which presented to CD4+ T cells (Ferrante 
et al., 2008).
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The mechanism behind immunodominance and epitope selection via MHCII is not clearly 
understood. Past studies have suggested that many factors such as length of peptides, cathepsin 
sensitivity, available T cell repertoire, pMHCII affinity to T cell receptor, and DM susceptibility 
can influence epitope selection or immunodominance (Kim & Sadegh-Nasseri, 2015). Altogether 
these factors make epitope selection a complex process.
Currently, two models can explain how immunodominant epitopes might be selected. The 
“epitope accessibility” model assumes that immunodominant epitopes are easily accessible to 
MHCII binding groove and cathepsins, which process these epitopes (Dai, Steede, & Landry, 
2001). This model is supported by the evidence that many known immunodominant epitopes are 
located in the region of the protein included or adjacent to the more solvent-exposed C - or N - 
termini or flexible portion of the protein (Dai et al., 2001; Guillet, Lai, Briner, Smith, & Gefter, 
1986; Nepom et al., 2001; Thomas, Hsieh, Schauster, Mudd, & Wilner, 1980). The “kinetic 
stability” model assumes that immunodominant epitopes form highly stable complexes with 
MHCII (Lazarski et al., 2005). An important factor that can help explain stable peptide binding 
to MHCII is the peptide dissociation in the presence of DM. Using a broad set of peptides 
derived from the vaccinia virus, Yin et al. investigated factors like MHCII binding affinity 
(IC50), intrinsic half-life, and DM-mediated half-life to understand the factors contributing to 
peptide immunogenicity. The authors found that DM mediated half-life was an independent 
factor that identified MHCII epitopes (Yin, Calvo-Calle, Dominguez-Amorocho, & Stern, 2012). 
Based on these models, we can say that not one factor alone is responsible for selection of 
immunodominant epitope, and multiple factors drive the selection of immunodominant epitopes. 
Immunodominant epitope discovery remains the focus of many efforts to understand the immune 
response and for vaccine developments against various pathogens. One such effort is dedicated 
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to the construction of prediction algorithms. The advantage of in-silico predictions is that they 
can generate large binding datasets in a shorter time frame than the typical in-vitro assays, and 
they require fewer resources. Many algorithms such as NetMHCII 2.2, NetMHCIIpan 3.1, 
SMM-align, NN-align, and SYFPEITHI are currently available on-line (Karosiene et al., 2013; 
Nielsen & Lund, 2009; Nielsen, Lundegaard, & Lund, 2007). The Immune Epitope Database and 
Analysis Resource (IEDB) and SYFPEITHI are two major binding database sources for MHCI 
and MHCII. As of August 2012, the SYFPEITHI database contains 7000 peptide sequences that 
bind to MHCI and MHCII while the updated IEDB site shows that it contains 44,541 MHCII 
binding affinity data covering 26 allelic variants (IEDB and SYFPEITHI reference). Although 
predictive algorithms are used for both MHCI and MHCII, predictions for the former are 
relatively superior to the latter (Bisset & Fierz, 1993; Jensen et al., 2018). The reason for the 
difference in accuracy between MHCI and MHCII prediction models is not fully understood. For 
MHCII, large binding datasets are available for well-studied alleles, like DRB1*0101, 0301, 
0701, 1501, and a limited number of DP and DQ alleles, but they are scarce for more rare alleles, 
making it difficult to provide reliable predictions. A major difference between MHCI and MHCII 
lies in their binding grooves. While MHCI has a closed binding groove allowing for the binding 
of only 9-10-amino acid long peptides, MHCII has an open binding groove, which enables 
binding of peptides of various length (between 8-9 and 25 residues or more), longer peptides can 
slide across the open-ended binding site and potentially interact with the MHCII in different 
“registers” with each allele or across alleles. This phenomenon adds a layer of complication to 
the prediction for class II (Nielsen, Lund, Buus, & Lundegaard, 2010). MHCII peptide 
interaction is comprised of three main interactions: hydrophobic interaction between peptide and 
deep pockets at either end of the groove, H-bond network across the length of the groove which 
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involves binding to the peptide backbone, and t ionic interactions due to charged side chains of 
shallower pockets in the center of the groove (Nelson & Fremont, 1999). The ionic interaction 
may vary between different alleles. The peptide side-chain residues labeled as P1 through P9 
define the so-called “binding core”. Of these 9 positions, P1, P4, P6, and P9 correspond to major 
pockets in the MHCII where peptide side chains are encapsulated (Sato et al., 2000). Many 
algorithms focus on these 4-5 anchoring residues for their predictions (McSparron, Blythe, 
Zygouri, Doytchinova, & Flower, 2003; Sathiamurthy et al., 2003). Studies have shown that the 
MHCII can bind to peptides ranging in length from 9-25 amino-acid, and such longer peptides is 
also presented to CD4+ T cells (Chicz et al., 1992; Srinivasan, Domanico, Kaumaya, & Pierce, 
1993). These longer peptides have different binding cores which make it difficult to predict the 
anchor residues which will interact with the binding site and generate a better CD4+ T cell 
response, thus making MHCII epitope prediction difficult.
Studies have shown that algorithms indeed predict epitopes, but they also have a high degree of 
false positives (FP) and false negatives (FN) (Chaves, Lee, Nayak, Richards, & Sant, 2012), which 
is one of the reasons for the limited accuracy. The high degree of false positives in algorithms 
suggested that maybe there are epitopes that can bind to MHCII well but lack the features required 
for activation of CD4+ T cells. Consequently, one could speculate that improved predictions would 
depend less on either change made in training method or increased data sets and more on including 
those factors and parameters involved in the presentation of antigen but currently disregarded. 
Apart from binding to MHCII molecule, another factor which plays a pivotal role in 
immunodominant selection is the cleavage pattern of the protein and stability of pMHCII 
complexes in the presence of DM, but the algorithms that are currently available do not include 
DM-associated binding affinity and kinetics data in their training datasets.
27
As mentioned above, studies have shown that DM-mediated dissociation is one of the determinants 
which separate epitopes from non-epitopes. Investigating the IC50s has led to the finding that IC50 
correlation with CD4+ T cell response is not as strong as DM mediated dissociation (Yin et al., 
2012). This finding may not be 100% accurate as the study did not measure the IC50s in the 
presence of DM.
Here we used a set of peptides with known CD4+ T cell responses to study the DM activity and 
its relationship with the binding affinity of the peptides. To understand how DM affects the 
binding affinity of different epitopes, we measured the binding affinity of peptides derived from 
H1N1 hemagglutinin protein in the absence and presence of DM. For these peptides, a CD4+ T 
cell response had been already assessed by ELISPOT assay (Richards et al., 2007). We observed 
that in the presence of DM the binding affinity of epitopes with weaker CD4+ T cell response 
always decreases, whereas the binding affinity of epitopes with stronger CD4+ T cell response 
could either increase or decrease. We also evaluated the prediction efficiency of four known 
algorithms (NetMHCII, NetMHCIIpan, SMM-align, and NN-align) in comparison to DM- 
associated binding affinity. A comparison between measured and predicted binding affinity 
showed that the inclusion of DM leads to a better prediction as compared to the one from 
algorithms. Based on these observations we propose that DM-associated IC50 is a better predictor 
of immunodominant epitopes, and inclusion of peptide binding affinity data measured in the 
presence of DM would lead to more accurate algorithms.
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Materials and methods
Expression and purification of recombinant soluble protein DR1 and DM: Recombinant 
soluble empty (peptide free) HLA-DR1 was produced in stably transfected Drosophila S2 cell line. 
Supernatant from the culture collected after inducing with copper sulfate. DR1 was purified from 
the supernatant by using L243-immunoaffinity chromatography as previously published (Stern et 
al., 1994). FLAG-tagged HLA-DM was stably transfected in Drosophila S2 cell lines and was 
purified by using anti-FLAG crosslinked M2 beads as described (Richards et al., 2007).
Peptide synthesis: Seventy-four 18-mer peptides offset by 11 amino acids spanning the entire 
length of H1N1 influenza virus hemagglutinin protein were synthesized, for which a DR1- 
restricted CD4+ T cell response in a mouse model had been already measured (Richards et al., 
2007). These peptides were classified into four categories based upon CD4+ T cell response 
normalized to the response against peptide HA435-452 taken as a 100% reference: peptides with 
less than 5% response considered negative, those with 6 to 24% response considered weak and 
those with 25-60% response was considered subdominant. Any peptide showing at least 61% of 
the response was considered immunodominant. Five additional 15-mer peptides consistently 
reported within the top ten hits across algorithms were selected and synthesized to assess the 
impact of length on the binding. Peptide IDs and corresponding sequences are listed in Table I. 
Biotinylated-HA306-318 (GPKYVKQNTLKLAT) from influenza A virus H3 subtype was used as a 
benchmark peptide in competition binding assays. Five 15-mer peptides representing shorter 
variations of the 18-mer peptides HA204-221 and HA435-452 were also synthesized. Peptides 
were synthesized by Anaspec Inc and ABI Scientific using Fmoc chemistry and fully automated 
multiple peptide synthesizer. Peptides had greater than 90% purity and verified by reverse-phase 
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HPLC and mass spectrometry. Peptides were dissolved in 10-100% DMSO based on their 
solubility and stored at -20°C.
Competition Binding Assay: Inhibition constant (IC50) for each peptide was measured as 
described (Ferrante & Gorski, 2012). Briefly, 40 nM DR1 was incubated with 40 nM biotinylated 
HA (bioHA) peptide in citrate-phosphate buffer pH 5.4 (0.1% BSA, 0.01% Tween 20, 0.1 mM 
iodoacetamide, 5 mM EDTA, 0.02% NaN3) in the presence of varying amounts of inhibitor 
peptides (2.5 mM to pM) for 3 days at 37oC. The incubation time ensured that over >65% of the 
DR1 protein participates in the peptide-binding reaction to reach equilibrium. To measure the IC50 
values in the presence of DM, 240 nM DM added along with DR1 during reaction setup. The 
bound biotinylated peptide was detected using a solid-phase immunoassay, and Eu2+ labeled 
streptavidin. Plates were read using a Wallac VICTOR counter (PerkinElmer Wallac). Data was 
fit to logistic equation y= a/ [1+ (x/x0) b] by using Systat SigmaPlot. IC50 values obtained from the 
curve fit of the binding data. Each experiment was performed in quadruplicate and three individual 
experiments performed for each peptide. The mean of the three experiments was plotted to 
calculate the IC50 of each peptide. IC50 values can be used to calculate the equilibrium dissociation 
constant (Kd). Kd values for each peptide can be calculated by using Cheng-Prusoff equation Kd = 
(IC50)/(1+[bioHA]/Kd bioHA) (Yung-ChiCheng, 1973). As Kd usually used as the measure of the 
binding affinity, here we have used IC50 as a proxy for binding affinity as IEDB uses IC50 values 
as a measure for epitope binding to MHCII.
IC50 predictions using algorithms: Four algorithms: NetMHCII 2.3, NetMHCIIpan 3.2, NN- 
align, and SMM-align (Karosiene et al., 2013; Nielsen & Lund, 2009; Nielsen et al., 2007) were 
used for predicting IC50 of the peptides under scrutiny. NetMHCII 2.3 and NetMHCIIpan 3.2 were 
the most updated version as of August 2018. The entire sequence of the HA protein from the 
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human influenza A/New Caledonia/20/99 (H1N1; Uniprot ID: QWG600) was inserted into the 
website to predict the IC50 of each peptide. NetMHCII 2.3 and NetMHCIIpan 3.2 predicted the 
IC50 for 18-mer peptides, and SMM-align and NN-align predicted IC50 for 15-mer peptides. SMM- 
align and NN-align predictions were made on 01/04/2018 using the IEDB analysis resource SMM- 
align and NN-align tool (Nielsen & Lund, 2009; Nielsen et al., 2007).
Unpaired two-tailed t-test and one-way Analysis of Variance (ANOVA): Unpaired two-tailed 
t-test and one-way ANOVA was performed by using Graph prism5. These tests were performed 
to determine if the IC50s measured by competition binding assay without and with DM are 
significantly different between the four categories of peptides distinguished by Richards et al. 
2007. We employed unpaired two-tailed t-test to compared immunodominant peptide with other 
categories of the peptides (subdominant, weak, and negative) while one-way ANOVA was used 
to compared immunodominant, subdominant, weak, and negative peptides.
Comparative analysis of predicting IC50 and measured IC50 by using receiver operating 
characteristic (ROC) curves and area under the curve (AUC) scores: Each binding prediction 
method compared with the epitopes identified by ELISPOT assay. Peptides with greater than 5% 
proliferation of CD4+ T cell response as compared to the HA435-452 (the reference peptide) were 
considered as an epitope for ELISPOT analysis. Prediction accuracy was measured as described 
(Chaves et al., 2012). False-positive (FP), false negative (FN), true positive (TP), and true negative 
(TN) rates were calculated for each method. For ELISPOT analysis, peptides which were binding 
and eliciting a T cell response were considered TP, peptides which were binding but not eliciting 
a T cell response were considered FP, peptides which did not bind nor elicited a T cell response 
were considered TN and peptides which did not bind but elicited a T cell response were considered 
as FN. Since algorithms are designed to predict binding, we set IC50 threshold to 5000 nM as per 
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IEDB recommendation, such that any peptide with IC50 greater than 5000 nM does not activate T 
cell.
True positive rate (TPR) = (TP/TP+FN) and False positive rate (FPR) = (FP/FP+ TN) were 
calculated. ROC curve was generated by plotting FPR against TPR using Graph Prism5. AUC 
values from the curves were used to calculate the prediction accuracy of each method. The 
prediction accuracy of algorithms was also calculated for a binding method without and with DM, 
as described above. To calculate the TP, TN, FP, and FN we differentiate between the epitope and 
non-epitope. In our binding assay, some peptides did not show binding at all; such peptides 
considered non-epitope while remaining peptide, which shows binding, were considered epitope.
32
Results
Binding affinity of weaker epitopes is reduced by the presence of DM more consistently than 
for dominant epitopes: To understand whether the addition of DM has an impact on the affinity 
of peptides classified according to their CD4+ T cell response, we measured IC50 of a set of 
peptides. These peptides were derived from hemagglutinin protein of the H1N1 influenza virus for 
which a DR1-restricted CD4+ T cell immunodominance hierarchy had been already established 
(Richards et al., 2007). In the original report, transgenic DR1 mice intranasally were infected with 
A/New Caledonia/20/99 at 2-4 months of age. These mice were sacrificed, and spleen was used as 
a source of CD4+ T cells for ELISPOT assay. The entire sequence of the hemagglutinin protein 
was covered by eighty 18-mer peptides overlapped by 11 amino acids, were synthesized, and the 
peptide-dependent CD4+ T cell response was measured. These peptides were categorized into four 
categories based on their CD4+ T cell response, as shown in Table 2: Immunodominant (6 
peptides), subdominant (6 peptides), weak (29 peptides) and negative (39 peptides). We measured 
the IC50 of all 74 peptides both in the absence and presence of DM using a competition binding 
assays (CBA) with biotinylated HA306-318 as our reference sequence (Table 3). Various 
concentrations of unlabeled test peptides could compete against biotinylated HA306-318 for binding 
to DR1 in the absence of DM or along with 3-fold excess of DM. DR1 bound to biotinylated HA306- 
318 was measured by using Eu+2 labeled streptavidin in a solid-phase assay.
To test whether there is any difference between IC50 values measured by our system based on the 
CD4+ T cell response (as determined by Richards et al. 2007), we plotted logIC50 values of 
peptides from individual categories (immunodominant, subdominant, weak and negative) and 
performed one-way ANOVA. We tested these for IC50 values in the absence and presence of DM. 
As shown in Figure 2.1A, there was a significant difference between immunodominant and weak 
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(p<0.05), immunodominant, and negative (p<0.05) and subdominant and weak (p<0.05). The 
absence of DM was not revealing a comparable difference between the individual peptide 
categories (data not shown). This indicates that the inclusion of DM can help distinguish between
peptides eliciting different CD4+ T cell responses.
Figure 2.1: Inclusion of DM impact the binding affinity of weaker epitopes: (A) One-way 
ANOVA test performed for all four categories of peptides (immunodominant, subdominant, 
weak and negative). Two-tailed unpaired t-test between binding experiments performed in the 
absence and in the presence of DM was performed for (B) all peptides, (C) weak and negative 
peptides, (D) immunodominant and subdominant peptides.
To understand how DM presence impacts the IC50 of the tested peptides, we ran a set of two-tailed 
unpaired t-test on IC50 values of the peptides measured in the absence and presence of DM. Upon 
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comparing the log IC50 of peptides with and without DM, irrespective of their CD4+ T cell 
response, we found the IC50 values to be significantly different (P<0.0001), as shown in Figure 
2.1B. The inclusion of DM significantly reduced the IC50 values of the peptides. Next, to check if 
this drop in IC50 values is across all the peptides or restricted to only a few peptides, we analyzed 
the logIC50 of peptides based on their CD4+ T cell response categories, without and with DM. We 
found that weak and negative peptides had an IC50 significantly different (P<0.0001), as shown in 
Figure 2.1C, due to the presence of DM while immunodominant and subdominant peptides did not 
show a change in IC50 values, as shown in Figure 2.1D. These indicate that DM-associated binding 
change directly correlates to CD4+ T cell response.
DM-associated IC50 is significantly different for immunodominant peptides when compared 
to other peptides: To see if the inclusion of DM in measuring peptide binding affinity can help 
distinguish between immunodominant peptides and other peptides categories we plotted logIC50 
values of immunodominant peptides against the remaining peptide categories (subdominant, weak 
and negative). As shown in Figure 2.2A, we found that the IC50 values of immunodominant 
peptides without DM is not significantly different from the remaining peptides (n = 3, p = 0.18, 
unpaired t-test). On the other hand, as shown in Figure 2.2B, the presence of DM led to the IC50 
values of immunodominant peptides to be significantly different (n = 3, p = 0.0028, unpaired t- 
test). We also ran the unpaired t-test where we check subdominant, weak, and negative individually 
against remaining peptides (data not shown) to test if there IC50 is different. Only weak peptides 
IC50 values were significantly different from remaining peptides IC50 values. The IC50 values of 
weak peptides were different from other categories irrespective of DM presence. Based on this
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observation, we conclude that DM-associated IC50 is a significant determinant of
immunodominant epitopes but not of others.
Figure 2.2: DM-associated IC50 is significantly different for immunodominant peptide: Two­
tailed unpaired t-test between immunodominant peptides and other peptides (subdominant, weak, 
and negative) performed for (A) IC50 in the absence of DM, (B) IC50 in the presence of DM.
Predictive IC50 values differ from measured IC50: In the last two decades, various online 
algorithms have been developed to predict the MHC epitopes (Bisset & Fierz, 1993). They 
predicted MHC-peptide affinity and used them as a proxy for the T-cell epitope. However, various 
studies have shown that these algorithms' efficiency for MHCII is lower than MHCI due to the 
high number of false-positive epitopes (Chaves et al., 2012). We assessed the accuracy of IC50 
values predicted by different algorithms as opposed to experimentally determined IC50 values. We 
used different on-line available algorithms to predict the IC50 values of the peptides tested in 
competition binding assay and only considered IC50 values in the absence of DM since all current 
algorithms trained on uncatalyzed peptide-binding datasets. While NetMHCIIpan 3.2 and 
NetMHCII 2.3 could predict IC50 values for 18 amino acid peptides, SMM-align and NN-align 
predicted IC50 values for 15 amino acid peptides. As shown in Table II, predicted IC50 values were 
within a range of 6 nM to 24000 nM, while measured IC50 values were above 40 nM. Upon plotting 
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a heat map to display the difference between the measured and predicted IC50 of each peptide, as 
shown in Figure 2.3, we concluded that measured IC50 values were mostly in the μM range, while 
predicted IC50 values were mostly in the nM range. Comparison of the IC50 generated in vitro and 
in silico using a one-way ANOVA revealed a significant difference between measured and 
predicted IC50 (data not shown, p<0.05).
On ranking these peptides based on their binding affinity (data not shown), NN- and SMM- align 
showed the weak and negative peptides HA526-543 and HA533-550, respectively as rank 1, and 
both NetMHCII algorithms showed the negative peptide HA267-284 as rank 1. The 
immunodominant peptide HA440-455 always ranked in the top ten as per algorithm predictions. 
Our binding assay identified the negative peptide HA267-284 to be ranked one, followed by 
immunodominant peptide HA162-179 in the absence of DM, while immunodominant peptide 
HA204-221 was ranked 1 in the presence of DM. These findings indicate that the competition 
binding assay with DM was more accurate in identifying the immunodominant epitope.
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Figure 2.3: Heatmap of binding affinity for peptides derived from hemagglutinin protein for which 
CD4+ T cell restricted immunodominance hierarchy is already established (Richards et al. 2007). 
IC50 for each peptide is measured by competition binding assay in the presence and absence of 
DM. IC50 for each peptide also predicted by algorithms NetMHCIIpan 3.2, NetMHCII2.3, NN- 
align, and SMM-align. A comparison between predicted and measured IC50 showed that predicted 
and measured IC50 has a significant difference in their values. For algorithms mostly, a peptide 
with weaker immune response showed better binding affinity while in measured IC50 peptide with 
stronger immune response as well as weaker response showed comparable binding affinity. For 
with DM, the top peptide was the one with a stronger immune response, and in the presence of 
DM affinity for a weaker response, peptide always decreased.
Accounting for peptide length did not improve the predictions: SMM-align and NN-align do 
not provide the option for selecting the length of the peptide, so we used the result of the 15-mer 
prediction for the comparison with the experimental IC50 of the 18-mer peptide. To see if the length 
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of the peptide is a factor for the difference between predicted and measured IC50 values we measure 
the binding affinity of selected 15-mer peptides derived from immunodominant peptide HA204- 
221 and HA435-452. To obtain the 15-mer peptides we fed the sequence of the peptide in the 
IEDB database and selected the top 10 percentile peptides for our binding assay. As shown in 
Table II, there is a significant difference between measured and predicted IC50 values. These results 
point to the likelihood that peptide length is not a factor responsible for the difference between 
experimental and predicted binding affinity values as we noted for SMM and NN-align.
DM-mediated binding affinity improves the epitope prediction: Next, we wanted to test which 
method is better in predicting immunogenicity. We tested the efficiency of CBA without DM, 
CBA with DM, and web-based available algorithms. IEDB recommendations were used to classify 
the peptides as binder v/s non-binders. IEDB proposes the following recommendations for 
classifying affinity based on the IC50 values: high (IC50 values <50 nM), intermediate (IC50 values 
>50 and <500 nM), and low (IC50 values >500 and <5000 nM). Peptides with IC50 values >5000 
nM are not known to be viable T cell epitopes, so we classified such peptides as non-binders (These 
peptides are different from the peptides for which we have no binding in our binding assay). Based 
on this classification, 25 out of the 74 peptides had an IC50 <5000 nM. We found that 35 peptides 
had an IC50 >5000 nM, and 14 peptides were not competitive at all in our binding assay for DR1 
in the absence of DM. On the other hand, eight peptides showed IC50 <5000 nM, 51 peptides 
showed IC50 >5000 nM, and 15 peptides showed no binding at all for DR1 in the presence of DM. 
Out of the six immunodominant peptides, 4 featured an IC50 <5000 nM and 2 featured IC50 >5000 
nM for DR1 in the absence of DM. When DM added in the binding assay, 50% of the 
immunodominant peptides showed an IC50 value greater than 5000 nM.
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To check which method is best for prediction, we plotted the ROC curve for each in vitro and in 
silico approach, using the published ELISPOT assay data to define positive and negative epitopes. 
TP, FP, TN, and FN values were calculated for each threshold along with TPR and FPR, as 
described in methods. AUC values of the ROC curves calculated where 1 represents a perfect 
predictor, and 0.5 represents a random algorithm. We plotted three ROC curves for the overall 
comparison between different binding methods. First, we compare all the binding methods against 
the ELISPOT assay data. To differentiate between epitope and non-epitope we set the cut-off at 
5%. Any peptide with CD4+ T cell response >5% was considered an epitope. Upon plotting the 
TPR and FPR values for peptides which have IC50 <5000 nM (IEDB recommendations that no 
known T cell epitope has IC50 >5000 nM) CBA with DM had the highest AUC value of 0.84 (Table 
1) as compared to other methods which were very close to 0.5 values (Figure 2.4A). We 
hypothesize that DM is better for predictions when epitopes IC50 value cutoff set to <5000 nM. 
This is because we cover fewer FP epitopes. This becomes clear when we plot a ROC curve for 
CBA with and without DM (data not shown) up to 50000 nM which were the maximum IC50 value 
we calculated by using our binding assay. We observed that CBA with DM has its AUC value 
decreased to 0.68, and for CBA without DM has its AUC values decreased from 0.68 to 0.63.
NetMHCII provided the most accurate predictions compared to other algorithms: Next, we 
wanted to analyze which algorithm is better in predicting binding affinity upon comparing CBA 
as a method to select epitope. TP, FP, TN, and FN were measured as follows: peptides which 
predict binding, and for which we also observed binding in our method, were considered TP, 
peptides which predicted binding but did not show binding in our method considered as FP, 
peptides which predicted no binding (IC50 >5000 nM) and did not show binding in our method 
were considered as TN, and finally the peptides which were predicted no binding but shows 
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binding in our method were considered FN. In the past, it had been demonstrated that NetMHCII 
2.2 performed better compared to NetMHCIIPan 3.1 when a large number of peptides were tested 
(Chaves et al., 2012). When testing with CBA without DM, we found that NetMHCII 2.3 (updated 
version) and NN align better in prediction with an AUC value of 0.84, as shown in Figure 2.4B 
while for CBA with DM, NetMHCII 2.3 was better in prediction with an AUC value of 0.86, as 
shown in Figure 2.4C. Even for comparison with the ELISPOT assay, the highest AUC value was 
NetMHCII 2.3 with AUC value of 0.67. Thus, our findings were consistent with previous literature 
indicating that NetMHCII latest version is better in prediction among the chosen four algorithms.




CBA w/o DM 0.68 0.34
CBA w DM 0.84 0.07
NetMHCIIpan 3.2 0.56 0.67





NetMHCIIpan 3.2 0.81 0.011





NetMHCIIpan 3.2 0.80 0.013




Figure 2.4: ROC curve and area under the curve (AUC) values for different binding methods. 
CBA with DM is better in prediction. A. ROC curve for comparison between measured IC50 and 
predicted IC50 to determine the method best for prediction of the epitope. NetMHCII 2.3 is a 
better predictor of binding when compared with other algorithms. B. ROC curve for comparison 
between different algorithms with competition binding assay without DM. C. ROC curve for 





Immunodominant epitope discovery remains the focus of many studies along with online- 
available prediction tools. The available online algorithms are not as efficient for MHCII epitope 
prediction as they are for MHCI. The reason for the lower accuracy rate for MHCII is mainly due 
to a high rate of false-positive epitopes. The high rate of false positives can be partially explained 
to omitting various factors that are known to be involved in epitope selection. One of the crucial 
factors which are not considered in the training dataset is DM activity. Previously published 
studies have investigated the role of DM in shaping the peptide repertoire by using DM-mediated 
half-life and DM-susceptibility (Yin et al., 2012). It is well established that DM accelerates the 
exchange of peptides and helps in the selection of kinetically stable MHCII-peptide (Yin, 
Maben, Becerra, & Stern, 2015). It is not very well studied how binding affinity (IC50) of 
peptides would change in the presence of DM and if this factor can be used as a correlate of 
immunodominance.
To understand whether the DM-associated binding affinity can help in identifying 
immunodominant epitopes and whether DM can improve epitope prediction, we used peptides 
from hemagglutinin protein of H1N1 influenza virus, for which a DR1-restricted CD4+ T cell 
immunodominance hierarchy had been already established. The peptides classified into four 
categories based on their CD4+ T cell response: immunodominant, subdominant, weak, and 
negative, where immunodominant peptides showed the strongest T cell response and negative 
peptides showed the weakest T cell response. We measured the IC50 values for each of these 
peptides in the absence and presence of DM. Upon comparing the IC50 values of 
immunodominant peptides against the pool of the other three categories of peptides, we found 
that IC50 measured in the presence of DM was significantly different. We also studied the impact 
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of DM on the IC50 values of the peptides irrespective of their categories (Figure 1A) and found 
that there was a significant change in the IC50 values due to the presence of DM. When the 
individual category of the peptides was tested using ANOVA, we observed that for weak and 
negative peptides there was a significant difference between without and with DM IC50 values 
but not so for immunodominant and subdominant peptides. Taken all together these results 
showed that DM has significantly altered the binding affinity of the peptides for MHCII, and the 
impact of DM action is more significant on peptides with weaker CD4+ T cell response.
Another critical observation seen in our analysis is that certain peptides, like HA267-284 or 
HA323-340, which are associated with a weaker CD4+ T cell response, featured a binding affinity 
greater than peptides eliciting a stronger immune response. These results illustrate that a strong 
association with MHCII alone cannot determine the strong CD4+ T cell response. The binding 
affinity for these peptides reduced 22-fold and 6-fold in the presence of DM. These demonstrates 
that DM might be one of the factors which can explain the rationale behind how peptides with a 
greater binding affinity generate a weaker immune response.
Currently, available epitope prediction algorithms focus on binding affinity as a major factor 
because it is an essential step during antigen processing, and binding interaction between MHCII 
and antigen will also determine its capability to activate CD4+ T cells to generate an immune 
response. To ascertain the accuracy of such algorithms for the experimental epitopes adopted in 
our study, we tested the difference between measured and predicted binding affinity. We observed 
that the gap between these two values is significant. When we assessed the accuracy of the 
algorithm and competition binding assay, we found that competition binding assay with DM shows 
the best prediction with an AUC value of 0.84. We also compared different algorithms with each 
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other and found that NetMHCII's latest version is better in prediction compared to all the tested 
algorithms. This result is consistent with previously published studies (Chaves et al., 2012). Upon 
comparing various updated versions of these algorithms, there has been not much difference in 
terms of predictions. These results are due to not considering all the factors which are involved in 
MHCII antigen processing. Studies are started to investigate cathepsin cleavage (Schneidman- 
Duhovny et al., 2018) and role of flanking region in the activation of CD4+ T cells after binding 
affinity, but DM still neglected.
Current literature has shown that in the case of MHCII, the flanking residues on both N-termini 
and C-termini of an antigen can play a role in the activation of CD4+ T cells. Length of the peptide 
is an essential factor that can alter the antigen immune response. More recent studies have begun 
to focus on this element and started including the length of peptides in MHCII antigen prediction. 
Recently IEDB has introduced a new binding prediction method, which predicts the cleavage 
pattern as well as the binding affinity of an antigen; the performance of this new prediction method 
appeared to be better than the algorithms which only predict binding affinity.
DM is a non-classical molecule that removes CLIP from a newly synthesized MHCII so that the 
antigen can bind to MHCII. Studies have shown that DM catalyzes the exchange of peptides and 
selects for kinetically stable peptide-MHCII complex (Ferrante, 2013). Immunodominant peptides 
generally show DM resistance, while peptides with weaker immune response appear to be DM- 
sensitive. Upon comparison between DM associated binding affinity with CD4+ T cell response, 
we observed that the peptide with the weaker immune response always loses binding capability in 
presence of DM. This can be reconducted to DM ability to exchange peptide where it can 
accelerate the off rate, thus possibly decreasing the binding affinity of such antigens. For 
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immunodominant peptide we observed that the binding affinity could either increase or decrease. 
The possible explanation for immunodominant peptides not showing a one-directional shift in 
binding affinity could be the length of the peptide, which can affect the DM action on the peptide 
exchange. The example of such a mechanism is seen in case of few peptides, for instance, HA442- 
459, which is an 18-mer with decreased affinity in the presence of DM, but HA440-455, which is 
the same sequence but 16-mer with
better affinity in the presence of DM. Thus, a difference of 2amino acids can drastically change 
DM action, with the consequence that an antigen cleavage pattern can dictate the outcome of DM 
action. Indeed, an additional question our group is addressing concerns the possible correlation 
between CD4+ T cell response and cathepsin resistance and between cathepsin and DM activity. 
MHCII antigen processing is a complex process, and binding affinity alone cannot predict 
immunodominance accurately. To generate a better performing algorithm, integration of the 
various factors affecting antigen selection is needed, starting from DM-associated IC50 
measurements, with evident impact on our capacity to efficiently and effectively assess 
immunodominance in a high-throughput, low-cost fashion.
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Table 2.2: Peptides derived from the hemagglutinin protein of the H1N1 influenza virus used in 
this study. Based on the ELISPOT assay result (Richards et al. 2007) peptides were categorized 
into immunodominant, subdominant, weak and negative. The percentage of CD4+ T cell 
response measured against response generated by immunodominant peptide HA435-452. 
Peptides with less than 5% response were considered negative, those with 6 to 24% response 
considered weak, and those with a 25-60% response were considered subdominant. Any peptide 
with > 61% of the response considered immunodominant. 15-mer modified peptides were 
selected from the results of in-silico predictions in that they ranked among the highest ten 
scoring peptides across algorithms, and they contained binding motifs of experimental 
immunodominant peptides.





















































































HA204-218 Modified 15-mer Qralyhtenayvsvv
HA205-219 Modified 15-mer Ralyhtenayvsvvs
HA206-220 Modified 15-mer Alyhtenayvsvvss
HA437-451 Modified 15-mer Ynaellvllenertl
HA438-452 Modified 15-mer Naellvllenertld
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Table 2.3: IC50 for HA peptides measured by using competition binding assay in the absence 
and presence of DM and as predicted by NetMHCIIpan 3.2, NetMHCII 2.3, SMM-align (15 aa 
and 18 aa and NN-align (15 aa). NS: not synthesized due to difficulty in the synthesis. NB: no 
binding experimentally observed. LB: low binding; the peptide shows minimal competition 























HA1-18 8800 200000 462.09 731.9 37 40.1 92
HA8-25 NS NS 445.66 219.3 111 19.8 234
HA15-




0 3993.87 9533.8 164 884.4 443
HA29-




0 1342.56 6854.4 449 191.1 1050
HA43-
60 NB NB 2890.61 2880.1 825 1230.9 1702
HA50-
67 607 15700 318.02 444.3 3888 419.7 266
HA57-
74 561 44200 77.97 39.9 21 12.9 56
HA64-
81 26700 300000 641.19 283.9 265 105 614
HA71-
88 21500 400000 949.07 1312.4 835 2248.3 1149
HA78-




0 400000 627.21 1219.2 829 425.9 1388
HA92-
109 5200 6920 1153.63 3390.8 573 93.3 1496
HA99-




123 2800 100000 2803.89 7804.1 2360 4042.8 257
HA113-































144 NB NB 1063.23 2641.1 683 1416.1 1595
HA134-
151 36000 300000 4101.07 5262.6 2344 1528.1 1221
HA141-
158 400000 600000 1890.97 1760 127 120.3 342
HA148-
165 21300 200000 3410.16 3729 3071 2357 4045
HA155-
172 7050 43300 245.27 106.3 94 36.2 186
HA162-
179 98 1420 307.35 373.8 139 29.6 295
HA169-
186 NB NB 642.02 1122.5 155 186.4 373
HA176-
193 4700 60600 1625.37 1231.9 522 1319.2 1250
HA183-
200 5000 51600 962.01 3081.9 556 135 1308
HA190-
207 86000 500000 1454.13 1420.5 870 302.6 1910
HA197-
214 100000 700000 1705.25 2262.6 1177 1592.9 2603
HA204-
221 1420 401 61.64 30.7 69 10.1 188
HA211-
228 1290 33300 37.14 129.2 44 6.8 129
HA218-
235 5660 100000 316.5 154.6 721 563.2 997
HA225-
242 NB NB 805.77 499.1 1395 95.9 2080
HA232-
249 12200 65300 4027.15 3650.3 4290 1461.1 9371
HA239-
256 841 3410 322 229.6 1143 335.1 688
HA246-
263 306 6400 468.86 242.4 503 77.1 627
HA253-
270 40000 13300 89.62 43.5 97 39.9 249
HA260-



























284 84 1860 29.89 13.2 43 9.8 111
HA274-
291 NB NB 987.33 2985.5 443 456.8 734
HA281-
298
NB NB 8002.97 10748.3 1585 4012.4 1806
HA288-
305 NB NB 6466.75 9424.7 4379 2563.6 8246
HA295-
312 90900 3500000 806.38 1964.2 1370 2217.2 1258
HA302-
319 4600 200000 326.41 497 48 33.7 135
HA309-
326 900000 2700000 3675.85 5164.1 3376 2754.7 8339
HA316-
333 15200 400000 205.67 2706.7 59 84.6 142
HA323-
340 124 834 126.32 692.8 56 18.4 117
HA330-
347 213 4510 128.87 75.3 67 16.2 137
HA337-
354 2210 35500 324.05 748.2 140 25.7 156
HA344-
361 NS NS 559.14 1503.3 133 99.5 268
HA351-
368 4760 36700 1682.28 2621.3 1453 1049.5 2687
HA358-
375 NB NB 5201.05 5799.9 8909 5000.4 1866
HA365-
382 LB LB 5169.8 1685.7 498 1282.4 1445
HA372-
389 LB LB 4544.15 8468.3 2384 4087 5257
HA379-
396 LB NB 2001.28 6348.3 2448 3549.8 1442
HA386-
403 NS NS 1208.28 3326.2 373 586.6 1054
HA393-
410 1940 690 525.39 1103.6 114 683.3 278
HA400-


























424 10500 200000 1865.85 5187.7 866 2398.1 2219
HA414-
431 NB NB 4479.86 13326.4 1147 2637.6 3337
HA421- 2036
438 NB NB 5564.57 10845.2 7049 7780.4 9
HA428-
445 NS NS 317.09 252.1 149 28.5 173
HA435-
452 3080 2130 333.09 225.1 93 140.9 62
HA442-
459 1410 27300 1171.85 1119.3 84 25.7 87
HA449- 10000
466 0 1400000 2044.42 951.8 891 932 2047
HA456-
473 38000 800000 714.04 3136.6 36 66.1 99
HA463-
480 NB NB 3244.52 10681.5 421 1375.1 1239
HA470- 2404
487 4270 15080 5160.02 10426.2 8363 8154.4 8
HA477-
494 1670 3700000 2189.42 1488.8 4764 4998.8 1711
HA484-
501 NB NB 4932.28 3919.1 1302 1598.4 1313
HA491-
508 NB NB 6879.47 14497.9 4358 8144.7 4325
HA498- 50000
515 0 60000 5118.15 10735.6 3716 4044.3 8834
HA505-
522 NB NB 2677.36 4668.2 1165 4129.8 1551
HA512-
529 13300 46500 328.36 567.2 158 402.9 238
HA519-
536 3660 96300 274.85 1231.7 148 65.4 47
HA526-
543 4580 16100 72.87 322.6 19 6.8 10
HA533-
550 NS NS 253.24 621.1 11 9.1 10
HA540-

























565 603 17900 515.88 1624.4 131 23 360
HA440-
455 49800 9020 131.23 50.1 27 8.7 80
HA204-
218 701 441 24.4 8.4 69 10.10 69
HA205-
219 334 433 26.4 8.8 67 8.8 67
HA206-
220 1187 1236 43.3 15.2 73 12.9 73
HA437-
451 51658 12250 67.7 18.9 24 9 24
HA438-
452 5173 714 73.3 15.7 27 9.10 27
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Chapter 3: Alternate antigen presentation pathway for peptides generated from
Hemagglutinin protein2
2 Osan, J.K, Ferrante, A. Kuhn T. B (In Prep) Alternate antigen presentation pathway for peptides generated from 
Hemagglutinin protein.
Abstract
Classical antigen presentation pathway starts with antigen uptake at the surface of antigen­
presenting cells (APCs), which undergoes enzymatic cleavage through various endosomal 
compartments and binds to Class II major histocompatibility complex (MHCII) in MHCII 
compartments (MIIC). In the MIIC, antigenic peptides bind to MHCII in the presence of the non- 
classical MHCII molecule DM. Studies have shown the presentation of proteins through routes 
different from the classical pathway of antigen presentation and presented in the absence of the 
peptide editing factor HLA-DM (DM). In this study, we tested DM-susceptible 
immunodominant peptides under the hypothesis that they were selected through an alternate 
antigen presentation route by assessing their stability at acidic and neutral pH. Our results show 
that these immunodominant peptides showed greater stability at neutral pH as compared to acidic 
pH. We also tested length of the peptides based on the assumption that cleavage patterns can 
influence the presentation of the antigen. We showed that 15-mer peptides have greater stability 
at acidic pH as compared to 18-mer peptides. The 15-mer peptides also showed better stability 
with DM. Taken together these results indicated that DM-sensitive peptides of a certain length 
could nevertheless be presented and elicit a significant T cell response through favorable 
alternate pathways characterized by a less acidic environment.
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Introduction
Class II major histocompatibility complex (MHCII) are glycoproteins that present antigenic 
peptides at the surface of antigen-presenting cells (APCs) to CD4+ T cells for generating an 
immune response (Rothbard & Gefter, 1991). A pool of antigenic peptides is generated from 
enzymatic cleavage, but only a few of the peptides bind to MHCII and present to CD4+ T cells, 
and out of those presented peptides only a few of them generate efficient CD4+ T cell responses. 
These peptides which generate the main CD4+ T cell response are known as immunodominant 
peptides (Kim et al., 2014). A newly synthesized MHCII molecule consisting of α and β chain is 
assembled in the endoplasmic reticulum (ER) and transported through Golgi most often in the 
form of a nonameric complex to MHC class II compartment (MIIC). This nonameric complex 
comprises of three (αβ) dimers along with three invariant chains (Ii), which shield each peptide 
binding site and act as a chaperone for efficient transport of the MHCII multimer. In the MIIC, 
the invariant chain is cleaved into a shorter peptide named Class II-associated Ii peptide (CLIP). 
CLIP was removed from the binding site by HLA-DM (DM), a non-classical MHCII molecule, 
which enables the binding of antigenic peptides to MHCII. DM role is not only limited to 
removing CLIP, as a seminal work has shown inefficient antigen presentation in DM-deficient 
cells (Martin et al., 1996). Kinetic stability studies have shown that DM plays an essential role in 
generating stable peptide-MHCII (pMHCII) complexes by enhancing the release of less stable 
peptides. Additional observations indicate that DM-associated half-life is an independent factor 
for epitope selection. However, the mechanism of DM action is not clearly understood.
MHCII antigen presentation pathway starts when a pathogen is engulfed through endocytosis by 
APCs and transported through various endosomal vesicles to MIIC. Apart from deeper endo- 
lysosomal compartments, peptides potentially can bind in the early endosomal vesicles and 
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possibly on the surface of APCs (Qiu, Xu, Wandinger-Ness, Dalke, & Pierce, 1994; 
Santambrogio et al., 1999; West, Lucocq, & Watts, 1994). This other antigen presentation 
pathway is independent of classical factors like an invariant chain and DM, uses recycled 
MHCII, and it has been suggested that the peptide loading could be happening in a specialized 
compartment (Lindner & Unanue, 1996; Pinet, Malnati, & Long, 1994; Pinet & Long, 1998). 
This specialized compartment is an early endosome, where matured or recycled MHCII is 
present, but in the absence of DM, or a less active form thereof. These MHCII are not complexed 
to CLIP, and they are internalized from the surface of APCs (Pathak & Blum, 2000; Robinson & 
Delvig, 2002; ten Broeke, Wubbolts, & Stoorvogel, 2013). One of the studies showed the 
alternate presentation of HEL 48-61 immunodominant peptide, where the whole protein was 
presented in the absence of a newly synthesized MHCII molecule, which is a DM-independent 
pathway as the protein was bound to mature MHCII. This study also showed a difference in the 
SDS-stability for the HEL protein depending upon where it binds to MHCII. They showed HEL 
protein formed a SDS-unstable complex at the surface of APCs but a SDS-stable complex when 
bound to mature MHCII in endosomal compartment (Lindner & Unanue, 1996). MHCII in the 
presence of SDS buffer separates into α and β chains, but studies have shown that when bound to 
certain peptides after incubation at neutral pH, MHCII does not separate into its individual 
chains even in the presence of SDS buffer (Sadegh-Nasseri & Germain, 1991; Springer, 
Kaufman, Siddoway, Mann, & Strominger, 1977). pH is an essential factor that regulates the 
biological function of the endosomal compartment and the many molecules acting therein. DM 
activity is more efficient at late-endosomal pH (4.5 -6.0). The binding and kinetics of pMHCII 
impacted by the pH of the compartment in which the interaction takes place. The alternate 
antigen presentation pathway is also modulated by the pH of the compartment. Here, we present 
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a study in which we investigate the effect of pH on the behavior of DM-susceptible 
immunodominant peptides and correlate pH-sensitivity to SDS stability. For our research, we 
selected peptides derived from the hemagglutinin protein of the H1N1 influenza virus for which 
an HLA-DR1 (DR1)-restricted CD4+ T cell response already established. We measured the half­
life of the immunodominant peptides and showed their DM-susceptibility. Past studies have 
shown that hemagglutinin protein could be presented through a pathway that is independent of 
newly synthesized MHCII and invariant chain (Pinet et al., 1994). We used peptides derived 
from hemagglutinin protein with known CD4+ T cell response and measured their kinetics at 
acidic and neutral pH. We observed that immunodominant peptides showed slower dissociation 
at neutral pH as compared to acidic pH. These immunodominant peptides were DM-susceptible. 
We also measured their SDS-stability, and we observed that the majority of immunodominant 
peptides showed SDS-stability with few exceptions. We propose that these immunodominant 




Purification of HLA-DR1 and HLA-DM: HLA-DR1 (DR1) was co-transfected with alpha and 
beta chain in s2 Drosophila melanogaster cell line. DR1 was purified by using L243 cross-linked 
protein A sepharose beads (stern et al., 1994). HLA-DM (DM) was also expressed in the s2 
Drosophila melanogaster cell line. M2-anti flag affinity beads were used to purified DM 
(Hartman et al., 2010). purified proteins were stored in 50% pBs and 50% glycerol for long term 
storage.
Peptide synthesis: We selected FAM-labeled 18-mer peptides derived from the hemagglutinin 
protein of the H1N1 influenza virus for which cD4+ T cell response already measured in 
ELispOT assay (Richards et al., 2007). The sequence HA306-318 (GpKYvKQNTLKLAT) from 
influenza A virus H3 subtype was adopted as benchmark or competitor peptide as needed. 
Anaspec inc and ABi scientific synthesized peptides. peptides were synthesized using Fmoc 
chemistry and fully automated multiple peptide synthesizer. peptides have greater than 90% 
purity and verified by reverse-phase HpLc and mass spectrometry. peptides were dissolved in 
10-100% DMsO based on their solubility.
Fluorescence polarization assay: DR1 (5 μM) was incubated with a 4-fold excess of FAM- 
labeled peptides in citrate phosphate buffer (pH 5.4) for 18-24 hours at 37°C to form 
peptide/DR1 complexes (pDR1). pDR1 was then purified from unbound peptide by buffer 
exchange into pBs with centricon-30 spin filter that had been pre-incubated with 25mM MEs 
(pH 6.5). purified DR1/peptide complexes were then quantified by reading the Uv absorbance 
@ 280nm. Purified DR1∕peptide complexes (100 nM) were then incubated with ten μM 
unlabelled HA peptide and 300 nM of DM when needed at 37°C in a citrate-phosphate buffer 
(pH 5.4). The reaction was carried out in a black polystyrene 96-well plate and was covered with 
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mineral oil to prevent evaporation. Measurements were performed using Wallac VICTOR 
counter (Perkin Elmer Wallac) with the excitation wavelength = 485 nm and emission 
wavelength = 535 nm. Specific control groups included peptide only and buffer only and used 
for background correction. FP values transformed to fraction of bound peptide with the equation: 
P bound = (FPx - FPfree)∕(FPbound - FPfree), where FPx indicates the value of FP measured at t=x 
minutes, FPfree suggests the value of FP relative to free peptide, and FPbound indicates the value of 
fluorescence polarization of the complex (Ferrante, Templeton, Hoffman, & Castellini, 2015).
The fraction of bound peptide was then plotted against time and fit one- or a two-phase 
exponential function for half-life calculation.
SDS stability assay: 5 μM DR1 and a 20-fold excess of FAM-Iabelled peptides were incubated 
in phosphate buffer saline (PBS pH 7.4) for 16-24 hours. The unbound peptide was washed away 
using Centricon-30 spin filters. Complexes were incubated with laemmli buffer without β- 
mercaptoethanol and incubated for 15 minutes at room temperature. Samples were loaded on 4­




Immunodominant peptides showed DM susceptibility: DM-associated half-life is historically 
adopted as a measure of immunodominance/immunogenicity. it is well established that DM 
generates kinetically and energetically stable pMHcii complexes, which are presented to cD4+ 
T cells. Here, we adopted a set of peptides with known cD4+ T cell responses to ascertain 
whether peptides with greater T cell responses are resistant to DM-mediated release. We 
incubated purified soluble DR1 with excess fluorescein-labelled peptides overnight at 37°C. The 
excess peptide was removed by washing in centrifugal filtering microdevices with MWcO of 30 
kDa. 100 nM of complexes were loaded in black, low-retention plates without or with 300 nM of 
DM. The release of the peptide was measured overnight. Fp values were converted into a 
fraction of bound peptide and plotted against the time to calculate the half-life of each pDR1 The 
comparison between the half-life in the absence and presence of DM (as reported in Table 4) 
shows that the majority of peptides released faster in the presence of DM irrespective of their T- 
cell response. past studies have shown that cD4+ T cell epitopes feature a DM-associated half­
life > 6h, which is equivalent to the time the MHciis spend in the peptide loading compartment 
(Yin, calvo-calle, Dominguez-Amorocho, & stern, 2012). We observed that none of the 
immunodominant peptides under scrutiny showed a half-life of 6 hours or greater. This result 
indicates that these peptides are susceptible to DM action and therefore do not follow the 
canonical requirement for MHcii selection and presentation.
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Table 3.1: Kinetic stability of peptides derived from hemagglutinin protein. The half-life of the 
peptides measured at pH 5.4 in the absence and presence of DM.
Peptide Category Peptide Name T1/2 (minutes) (-DM) T1/2 (minutes) (+DM)






Subdominant H1A14 2625 960.93
H1A38 918.75 2187.5
Weak H1A08 839.06 42
H1A09 6289.06 109.37
H1A47 796.87 49






SDS-stability for immunodominant peptide abolishes at acidic pH: Lindner et al. have shown 
that HEK protein SDS-stability changes after being processed by APCs (Lindner & Unanue, 
1996). The partially folded HEK protein, when bound to recycled MHCII on the surface of the 
APCs, form unstable SDS-complex, but when they internalized, the complex dissociated. When 
the HEK internalized and bound to recycled MHCII in the endosome, it generates an SDS-stable 
complex while when HEK is internalized and processed through newly synthesized MHCII they 
generate SDS-stable HEK peptides. This study shows that there is a distinct pathway for a 
protein and its derived peptides based on the compartment where it internalizes and what kind of 
antigen processing machinery it exposes to. They showed the presentation of an antigen in DM- 
independent pathway where antigen bound to recycled MHCII. In our study we see that 
immunodominant peptides showed DM-susceptibility, which suggested that presentation of these 
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peptides might be DM-independent. Past studies have shown that SDS-stability is one of the 
properties, which is a sign of MHCII maturity, and immunodominant peptides showed SDS 
stability as one of the characteristics (Nelson, Petzold, & Unanue, 1993; Nelson, Roof, McCourt, 
& Unanue, 1992; Verreck et al., 1996). This suggests that SDS-stability may be required for 
efficient antigen presentation. To test if our peptides showed SDS-stability irrespective of DM- 
susceptibility, we tested SDS-stability for our peptides (mentioned in Table 4) which are derived 
from hemagglutinin protein of H1N1 influenza virus. Past studies have examined the SDS- 
stability at pH 7.4, but here we also tested the peptides SDS-stability when they formed at pH 
5.4. We incubated the fluorescent-labeled peptides with DR1 overnight at 37°C. The unbound 
labeled peptide was removed from the bound complex by extensive buffer wash. Complexes 
were incubated for 15 minutes at room temperature with a laemmli buffer without BME.
Samples ran on SDS-gel electrophoresis for an hour. Fluorescence was detected using a 
Typhoon scanner. The immunodominant peptides H1A440, H1A63, and H1A30 showed SDS 
stability along with the negative peptides H1A17 and H1A36, as shown in Figure 3.1A and B. 
We then tested SDS-stability for these peptides at pH 5.4, as shown in Figure 3.1C. We 
incubated the complexes at pH 5.4, and unbound peptide washed with PBS. Complexes were 
analyzed by SDS-PAGE. SDS stability was lost for H1A30 and negative peptide H1A36 when 
complexes were formed at pH 5.4 but not for the immunodominant peptide H1A440, H1A64 and 
negative peptide H1A17.
Kinetic and SDS-stability of immunodominant peptides dependent on the length of the 
peptides: Next, we wanted to test if the length of the peptides can alter the kinetics and SDS- 
stability of the above-tested peptides. Past studies have shown that peptide length influences the 
binding of the peptides to MHCII (O'Brien, Flower, & Feighery, 2008). We tested SDS-stability 
69
and kinetic stability of new 15-mer peptides derived from immunodominant H1A30 and H1A63 
by shortening the flanking ends. We also tested longer immunodominant peptides consisting of 
the overlapping H1A23, H1A24 (H1A2324), and H1A63, H1A64 (H1A6364). H16364 showed 
SDS-stability at pH 5.4 and 7.4 (Figure 3.1B and C). 15-mer derivatives of peptides H1A30 and 
H1A63 showed SDS-stability at pH 7.4 and 5.4 (Figure 3.1B and D). These observations suggest 
that based on peptide lengths the antigen could be presented through different presentation 
pathways.
Figure 3.1: SDS-stability of the peptides differs based on the pH of the reaction: 5 μM of DR1 
incubated with a 20-fold excess of fluorescence-labeled peptides overnight in PBS (A). SDS- 
stability of H1A440, H1A36, H1A29, H1A24, H1A17, H1A09 and H1A08 (B). SDS-stability of 
H1A30, H1A30-1, H1A30-2, H1A30-3, H1A63, H1A63-1 and H1A63-2. SDS-stability of 
peptides incubated in citrate-phosphate buffer (pH 5.4). The sample was also incubated with DM 
at time 0 and time 90 min. (C). SDS-stability of H1A440, H1A36, H1A2324 and H1A6364 (D). 
SDS-stability of H1A30-1, H1A30-2, H1A30-3, H1A63-1 and H1A63-2
We measured the half-life of 15-mer derivatives of H1A30 and H1A63 (Table 5). Two of the 15-
mer derivatives of H1A30 showed approximately 3-to-4-fold increase in half-life in the presence
of DM. In the case of H1A63 derivatives, the half-life increase showed only a 2-fold increase for 
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one of the derivatives. These results suggest that in the case of H1A30 and H1A63 the length of 
the peptides might be an essential factor in dictating DM activity.
Table 3.2: Kinetic stability of 15-mer derived from 30 and 63. The half-life of the peptides 
measured at pH 5.4 in the absence and presence of DM.
Peptide Category Peptide Name T1/2 (minutes) (-DM) T1/2 (minutes) (+DM)
H1A30 Derivative 30-1 11473 866.25
30-2 11503 770
30-3 6930 346.5
H1A63 Derivative 63-1 6930 223.5
63-2 11629 533.07
Immunodominant peptide H1A440, H1A30, and H1A23 are more stable at neutral pH: To 
test the hypothesis that immunodominant peptides H1A440 and H1A30 presented by binding at 
the surface of APCs, we incubated those peptides with DR1 at pH 7.4 and measured their release 
at pH 7.4 without DM. We observed that H1A440 half-life increased almost 7-fold, H1A23 up to 
4-fold, and H1A30 increased up to 2-fold (Table 6). H1A63 half-life did not increase 
significantly.
Table 3.3: Kinetic stability of selected immunodominant peptides measured at pH 7.4. Both 
incubation and release measured at pH 7.4.







The classical pathway of MHCII antigen presentation involves newly synthesized MHCII 
molecule, DM removal of CLIP from MHCII binding site, and exchange of antigen-derived 
peptides in the MIIC. Past studies have shown the existence of an alternate antigen processing 
pathway in which the antigen is presented through recycled MHCII at the surface of APCs (Pinet 
et al., 1994; Pinet, Vergelli, Martin, Bakke, & Long, 1995; Pinet & Long, 1998). This alternative 
pathway was analyzed for the processing and presentation of peptides generated from 
hemagglutinin protein, myelin basic protein and HEK protein (Lindner & Unanue, 1996; Pinet et 
al., 1994; Vergelli et al., 1997). Here, we tested a set of peptides with known CD4+ T cell 
responses derived from hemagglutinin protein for DM activity. Past studies have shown that 
DM-associated half-life is an independent factor of epitope prediction and in their studies, 
epitopes showed at least 6 hours of half-life in the presence of DM (Yin et al., 2012). The set of 
immunodominant peptides here analyzed showed a half-life of fewer than 6 hours in the presence 
of DM. We propose that these specific HA-derived immunodominant peptides is presented 
through an alternate, DM-independent pathway.
In our study, we selected peptides derived from H1N1 hemagglutinin protein, for which a DR1- 
restricted immunodominance hierarchy is already established. We measured the half-life of these 
peptides in the absence and presence of DM at pH 5.4. Unexpectedly, immunodominant 
peptides, along with weaker peptides, showed DM susceptibility. We also tested the SDS- 
stability of these peptides and observed that immunodominant sequences H1A30, H1A63, and 
H1A440 showed SDS-stability along with negative peptides H1A17, H1A36. The effect of pH 
tested along with SDS-stability showed that the SDS-stability of immunodominant peptide 
H1A30 abolishes at acidic pH. In contrast, the 15-mer derivatives tested within the 
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immunodominant peptides H1A30 showed SDS-stability even at acidic pH. We also measured 
the kinetic stability of these 15-mers at pH 5.4. These peptides showed greater kinetic stability in 
the presence of DM than the peptides from which they were originated. These results suggest 
that the observed DM susceptibility of these peptides could be due to the length of these peptides 
and can be presented through alternate pathways.
To test our hypothesis that these immunodominant peptides could be binding at the surface of 
APCs, we measured the half-life of these peptides at pH 7.4. H1A440 and H1A30 showed slower 
release at pH 7.4. DM is more active at acidic pH as these peptides are more stable at pH 7.4; 
these results suggest that these peptides presentation will be DM independent.
Our data showed that the antigen presentation of the hemagglutinin protein could be through 
various pathways. Currently, for immunodominant epitope selection, there are two models: 
kinetic stability and other one epitope accessibility. Kinetic stability model proposed that 
immunodominant pMHCII complexes have intrinsic stability, and DM helps in the selection of 
kinetically stable complexes (Yin et al., 2012; Yin, Maben, Becerra, & Stern, 2015). Epitope 
accessibility model suggests that immunodominant epitope selection is dictated by structural 
features of protein and accessibility to MHCII binding groove. This model indicates two paths 
for epitope accessibility: bind first, cut later and cut first, bind later (Kim et al., 2014; Kim & 
Sadegh-Nasseri, 2015). The classical pathway of MHCII presentation describes that antigens are 
first cleaved by cathepsins and later bind to MHCII in MIIC. Our study has two significant 
findings: 1. Kinetic stability of immunodominant peptides is pH-dependent which could rescue 
them from DM susceptibility 2. Immunodominant peptides stability is dependent on peptide 
length. Based on these findings we suggest that these immunodominant peptides are presented 
through alternate pathways where they would escape DM activity either by binding at the surface 
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of Apcs or by further trimming via cathepsins. Our results support a model in which multiple 
cross-over pathways coexist within the Apc and the outcome of the process is a consequence of 
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Chapter 4: Distinct Assembly of full-length HLA-DRI into nanodisc depends on the lipid 
composition3
3 Osan J.K., Rivera K., Ferrante A., Kuhn T. B. (In prep) Distinct assembly of full-length HLA-DR1 into nanodisc 
depends on the lipid composition.
Abstract
Class II major histocompatibility complex molecules (MHCII) are transmembrane glycoproteins 
found on the surface of antigen-presenting cells. MHCII expression is not limited to the cell 
surface, but it found in endosomal compartments, which have their signature membrane 
characteristics. They display to CD4+ T cells peptides that have been generated and selected by 
intracellular antigen processing and presentation mechanisms, thus initiating an adaptive immune 
response. The traditional strategy to investigate peptide binding to MHCII has relied on the 
expression and purification of soluble MHCII, in which the transmembrane portion of the protein 
is removed. One question address whether membrane-embedding of native MHCII impacts its 
function and interactions with peptides. To this end, full-length human MHCII allele HLA-DR1 
(DR1) was isolated from B-lymphoblastoid cell lines via immunoaffinity chromatography and 
subsequently incorporated into nanodiscs, synthetic model membrane device, to evaluate the 
potential effects of membrane lipid composition on MHCII assembly. Three types of nanodisc 
were generated: simple, fluid disordered, and rigid ordered, each of them characterized by unique 
lipid composition. Nanodiscs were separated using fast protein liquid chromatography (FPLC), 
indicating apparent differences between nanodisc types. Whereas fluid disordered nanodisc 
suggested DR1 assembly as a cluster (one major FPLC-generated peak), both rigid and 
straightforward nanodiscs revealed multiple peaks. As DR1 tends to form aggregates, we 
inferred that DR1 formed tetramers and dimers in simple and rigid nanodiscs. Our results 
indicate that membrane lipid composition has a substantial impact on native MHCII assembly 
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and possibly peptide interaction. We propose that MHcii conformation and activity are a 
function of the cell compartment where they reside at any point in time.
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Introduction
Class II major histocompatibility complex (MHCII) molecules are transmembrane glycoproteins 
expressed on the membrane of antigen-presenting cells (APCs) and endosomal compartment 
(Guillet, Lai, Briner, Smith, & Gefter, 1986). Upon infection, APCs uptake the pathogen and via 
the endo-lysosomal system, process the pathogenic proteins into smaller peptides, which can 
then attempt to bind to MHCII in the MIIC compartment. Selected peptide: MHCII complexes 
are presented to CD4+ T cells on the surface of APC, for engagement of the adaptive cellular 
immunity (Thomas, Hsieh, Schauster, Mudd, & Wilner, 1980).
MHCII is a heterodimeric membrane protein made up of α and β chains. These chains are 
glycosylated and have an extracellular domain, which contains the peptide-binding site, a 
transmembrane, and a cytoplasmic region (Gorga, Horejsi, Johnson, Raghupathy, & Strominger, 
1987). The cytoplasmic domain of MHCII plays an essential role in signaling to B cells (Harton 
& Bishop, 1993; Wade, Ward, Rosloniec, Barisas, & Freed, 1994). Cytoplasmic domain and the 
transmembrane portion of MHCII play a vital role in the efficient expression of MHCII on the 
plasma membrane (Wade et al., 1994). MHCII molecules incorporate into two types of 
microdomain: (i). Cholesterol and glycosphingolipid-enriched domains denoted lipid rafts (ii). 
Microdomains made up of tetraspan proteins, which enrich MHCII molecule loaded with 
peptides(Vogt, Spindeldreher, & Kropshofer, 2002). Studies have shown that the peptide-MHCII 
complexes are presented on dendritic cell surfaces in cholesterol-rich micro clusters and these 
clusters play an essential role in activating CD4 T cells (Bosch, Heipertz, Drake, & Roche, 
2013).
MHCII molecules tend to aggregate in the absence of peptide in their binding groove. Newly 
synthesized MHCII are rescued from such aggregation by forming a complex with invariant 
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chain, often as a nonamer ((αβ)3Ii3). Previous crystal structures have shown that MHCII can exist 
as a dimer of heterodimer (superdimers) (Brown et al., 2015). Studies have shown the presence 
of superdimers on the surface of mouse B cells and these superdimers show thermal and pH 
stability like MHCII dimer (Schafer, Malapati, Hanfelt, & Pierce, 1998). Superdimers were 
shown to be involved in T cell response to low-affinity antigens (Schafer & Pierce, 1994). 
To study the binding of MHCII and antigenic peptides, the extracellular domain of MHCII is 
usually expressed in insect cells and purified as a soluble protein. Studies have shown that the 
empty human MHCII, HLA-DR1 (DR1) expressed by insect cell line tends to aggregate, 
although it can be rescued by incubating with antigenic peptide (Stern & Wiley, 1992; Yin, 
Maben, Becerra, & Stern, 2015). Our group has observed that purified DR1 shows a band at 120 
kDa, and one at ~250 kDa, along with the usual dimer band at 56 kDa (data not shown here). It is 
possible that these aggregate or superdimers are DR1 bound to antibody (Hitzel, Gruneberg, van 
Ham, Trowsdale, & Koch, 1999); however, the DR1 fractions above 100 kDa are capable of 
binding the antigenic peptide HA306-318 (data not published), suggesting that these heavier 
fractions are DR1 superdimers. To understand how DR1 assembles in the membrane and 
whether superdimers also assemble in the membrane, we adopted nanodiscs as a surrogate of cell 
membranes.
Nanodiscs are a synthetic membrane model currently widely used to study the membrane 
proteins in their soluble form. They are composed of phospholipids encircled by amphipathic 
membrane scaffold protein (MSP). Nanodiscs are a self-assembly system where detergent 
solubilizes component of nanodisc assembled when detergent is slowly removed (Denisov & 
Sligar, 2017). Studies have shown that the assembly of the membrane proteins is dependent on 
the lipid environment (Amin & Hazelbauer, 2012). Phosphatidylcholine is the most used 
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synthetic lipids in nanodisc assembly. cholesterol, in combination with phosphatidylcholine, has 
been used previously for nanodisc preparation. The fluidity of the membrane depends upon the 
type and composition of lipids. Lipid rafts are sphingomyelin- and cholesterol-rich domains 
(Koukalova et al., 2017). By manipulating lipid ratios, fluid or rigid and ordered or disordered 
phases can be achieved in the nanodisc.
Here, we report the generation of a technology whereby full-length MHcii is used in a soluble 
form for application in biochemical assays. To this aim, we have taken advantage of an already 
established nanodisc assembly system. Full-length DR1 molecules from human B-cell 
lymphoblastoid cell lines were purified, which were subsequently embedded in nanodiscs during 
assembly. We also analyzed the effect of the lipid environment on the assembly of DR1 and its 
superdimers by changing the extent of fluidity and order of the nanodiscs. We observed a 
significant difference in DR1 assembly when different compositions of lipids used as well as the 
successful assembly of DR1 superdimers. These results suggest that the DR1 assembly within 
membranes is dependent on the lipid environment, and MHcii organization might be different in 
different compartments as a function of lipid composition.
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Materials and methods
Proteins and Lipids: Full-length HLA-DR1 (mDR1) was purified from B-cell lymphoblastoid 
cell lines (B-LcL), which were acquired from Fred Hutch research cell bank.
Msp1E3D1 protein (M7074-5MG) was ordered from sigma-Aldrich. The protein comes in a 
lyophilized form, which was stored in -20°C. The protein was dissolved in sterile water when 
ready for use.
1-palmitoyl-2-oleoyl-glycero-3-phosphocholine (pOpc), cholesterol and sphingomyelin lipids 
were used for the preparation of nanodisc. Lipids were purchased from Avanti polar Lipids. 
They were dissolved in chloroform and evaporated using dry N2. The dried lipids were further 
dissolved using cholate buffer (100 mM sodium cholate, 20 mM Tris-cL, 100 mM Nacl buffer). 
Purification of full-length DR1 from B-LCL: B-LcL was cultured in the laboratory, and 
mDR1 was purified from the cell culture. The cell suspension was spun down at 4°C, and intact 
cells were dissolved in 0.3 M sucrose lysis buffer. pellet was homogenized by using a Dounce 
homogenizer and further spun down to collect clear supernatant. pellet was also suspended using 
lysis buffer without sucrose, and the clear supernatant was collected. This clear supernatant is 
used to purify mDR1 by using immunoaffinity chromatography. The protein was stored in the 10 
mM Tris cL with 0.1% deoxycholate pH 8.0.
Nanodisc Preparation: Three types of nanodiscs as defined by their lipid compositions 
prepared: simple, fluid disordered, and rigid ordered. Ratios of lipids, MspE3D1, and mDR1 
used in the preparation of nanodisc reported in Table 7.
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Table 4.1: Description of lipids, MSPE3D1 and mDR1 ratios used in the preparation of different 
nanodiscs
Nanodisc Lipids MSPE3D1 mDR1
Simple 100 (POPC) 5 1
Simple 1000 (POPC) 10 1
Fluid-disordered 1000 (pOPC: PSM: Cholesterol: 60: 1: 1) 10 1
Rigid-ordered 1000 (pOPC: PSM: Cholesterol: 1: 1: 1) 10 1
To prepare nanodiscs, we made a reaction mix with the appropriate ratios of lipids, MSPE3D1, 
and mDR1, depending on the type of nanodisc. The reaction mixture was prepared in 100 mM 
sodium cholate, 20 mM Tris-CL, 100 mM NaCl buffer, and stored at 4oC for simple and fluid 
disordered nanodisc and @ RT for rigid disordered nanodisc for one hour. The detergent from 
the reaction mix was separated by incubating it with Biorad SM2 beads for 3 - 4 hours. Beads 
were removed from the mix, which finally contained nanodisc. Nanodiscs were stored at 4oC. 
Separation of nanodisc by using fast protein liquid chromatography (FPLC): To purify the 
nanodisc from any unbound protein and lipids, we used FPLC with an SEC 650 column. The 
separation was performed in 20 mM Tris-CL, 100 mM NaCl, pH 7.4 at a flow rate of 0.5 ml/min, 
and each aliquot of nanodisc were collected and further concentrated using Millipore centricon 
filter (MWCO 30 kDa).
Identification of nanodisc using gel electrophoresis: The FPLC-purified fractions were 
visualized in native polyacrylamide gel electrophoresis (PAGE) and SDS-PAGE to confirm the 
presence of nanodiscs. For both runs, we used mDR1 and MSPE3D1 alone as a control. Gels 
were stained with silver stain kit.
Identification of nanodisc using immunoblotting: Samples were run on 4-15% Tris-Glycine 
pre-cast gel purchased from Bio-Rad. 10 ug of total protein was loaded in each well. Proteins 
were resolved by SDS-electrophoresis by running at 120 Volts for 1 hour. Proteins were 
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transferred to a nitrocellulose membrane by running at 25 volts for 1 hour 45 minutes in 1X 
transfer buffer (25 mM Tris, 192 mM Glycine, 20% methanol). Membranes were blocked for 2 
hours at room temperature using 5% BsA in pBs. Blocked membranes were probed with 
primary antibodies against full-length DR1 (MEM-267 - monoclonal antibody raised in mouse­
specific to empty form of HLA-DR1) and Msp (anti-his monoclonal antibody raised in rabbit 
specific against 6*-His tag) by incubating overnight at 4o c. primary antibodies were detected by 
using secondary antibodies (goat-anti-mouse igG Alkaline phosphatase for anti-DR1 and goat- 
anti-rabbit igG Alkaline phosphatase for anti-his). Blot was developed by adding 5 ml of 
NBT/Bcip substrate solution.
Direct binding assay: 10 nM of nanodisc and control proteins was incubated with various 
concentration of biotinylated HA (bioHA) peptide in phosphate buffer saline (pBs) pH 7.4 
(0.1% BsA, 0.01% Tween 20, 0.1 mM iodoacetamide, 5 mM EDTA, 0.02% NaN3) for 5 days at 
37oc. For controls, soluble DR1 used as a positive control, and an empty nanodisc was used as a 
negative control. We tested fluid nanodisc and full-length DR1 alone for binding to bioHA. 
BioHA was serially diluted from 2.98 pM to 200 μM concentration. 20 nM of protein and 
nanodisc stock were prepared in PBS. In the reaction plate, 100 μl of protein solution and 100 μl 
of bioHA were added and incubated for 5 days at 37°C. L243 antibody was used to capture DR1, 
and an anti-his antibody was used to capture nanodisc. The incubation time ensured binding 
reaction to reach equilibrium. The bound biotinylated peptide was detected using a solid-phase 
immunoassay, and Eu2+ labeled streptavidin. plates were read using a Wallac viCTOR counter 
(perkinElmer Wallac). Each experiment performed in quadruplicate.
Binding with labeled peptides: 5 μM protein or nanodisc were incubated with 100 μM of a 
fluorescein-labeled peptide (HA306-318) in 20 mM Tris-CL and 100 mM sodium chloride buffer 
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(pH 7.4) overnight at 37°C. The unbound peptide was removed from the bound peptide by washing 
the complex with buffer ten times using an ultra-centrifugal filtering device with 30 kDa cutoff. 
10 μl of the complex was incubated with 10 μl of native loading buffer and loaded on precast 4­
15% Tris-Glycine gel. The gel was run using a native running buffer for 130 Volts for an hour. 
The labeled peptide was detected using a UV-transilluminator. Proteins were stained by using a 
silver stain kit. Silver stain and fluorescent bands positions were compared to identify the binding. 
Fluorescent bands were quantified by using ImageJ.
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Results
Assembly of full-length DR1 using one lipid shows differences based on the amount of lipid 
used in the nanodisc assembly mix: Nanodisc is a synthetic membrane model adopted to 
investigate the biophysics and biochemistry of membrane proteins. In this study, we used the 
nanodisc as a surrogate of the cell membrane to embed full-length MHCII proteins and 
investigate whether their conformations differ as a function of the nanodisc lipidic composition 
and ratio. As the MHCII allele, we used the commonly studied and widely available DR1. We 
purified the full-length DR1 from the B-lymphoblastoid cell line using immunoaffinity 
chromatography. First, we prepared simple nanodisc with one lipid (POPC) in the reaction mix 
to ascertain whether DR1 assemble in the nanodisc. The details of assembly mix are shown in 
Table 7. When we used 100: 5: 1 ratio (POPC: MSP1E3D1: mDR1), we observed on the FPLC 
chromatogram (Figure 4.1A) one major peak and two smaller peaks before the peak expected to 
contain the nanodisc assembled with DR1. We ran the FPLC fractions on native (Figure 4.1B) 
and SDS (Figure 4.1C) gel to identify the fraction-containing nanodisc. Nanodisc formation is 
confirmed by comparing nanodisc fractions with MSP and DR1 alone control lane on SDS and 
native PAGE. Nanodisc fractions run differently on native PAGE as compared to controls. In 
SDS PAGE we observed both MSP and DR1 band in the nanodisc fractions. For earlier small 
peak we found that tetramer and dimers of DR1 first assembled, and in the later fractions, all the 
forms of DR1 assembled. The most significant peak fractions show assembly of monomer DR1 
in majority amount. These observations indicate that different nanodiscs favor the incorporation 
of different conformations of DR1. Next, we prepared the nanodisc by using a different ratio of 
assembly mix 1000: 10: 1 ratio (POPC: MSP1E3D1: mDR1). As shown in Figure 4.1D, the 
FPLC chromatogram shows one major peak with a broader small peak before the major peak.
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When analyzed in SDS-PAGE (Figure 4.1E) we observed that the significant peak fraction 
contains all conformation of DR1 along with MSP. Taken together, these results indicate that the 
composition of the nanodisc assembly mix determines the conformation of DR1 embedded in the
assembly.
Figure 4.1: Assembly of full-length DR1 in the simple nanodisc. Assembly of DR1 differs as a 
function of lipid ratio in the nanodisc mix. Ratio of POPC: MSPE3D1: mDR1 (100: 5: 1) (A). 
FPLC chromatogram. (B). Native gel (C). SDS-PAGE gel Ratio of POPC: MSPE3D1: mDR1 
(1000:10:1) (D). FPLC Chromatogram (E). SDS-PAGE gel
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Assembly of full-length of DR1 in fluid-disordered nanodisc differs from rigid-ordered 
nanodisc: Lipid rafts are sphingomyelin- and cholesterol-enriched platforms in the plasma 
membrane (Koukalova et al., 2017). Based on the composition of the lipid ratio, the system can 
be rigid-ordered or fluid-disordered. Studies have shown that MHCII associates with lipid rafts 
membrane microdomains on the surface of APCs, and this association is essential for their ability 
to stimulate CD4+ T cells (Bosch et al., 2013). To mimic the MHCII in lipid rafts and study the 
effect of membrane composition on assembly of MHCII, we prepared two types of nanodiscs: 
fluid-disordered and rigid-ordered. Composition of fluid and rigid nanodiscs are shown in Table 
1. As shown in Figure4.2A, for fluid-disordered nanodiscs, we observed one single peak on the 
FPLC. The collected fractions run on native (Figure 4.2B) and SDS (Figure4.2C) gel revealing 
that all the fractions of the major peak have monomer and superdimers DR1 conformation in one 
form of nanodisc. Next, we prepared rigid-ordered nanodiscs with DR1 and analyzed with FPLC 
for separation and SDS gel for identification. We observed a major peak on the chromatogram 
(Figure 4.2D), but the peak was separated at the top making it look like a double peak. On the 
SDS gel (Figure 4.2E) we observed that the first half-peak has more amount of superdimers DR1 
while the second peak contains mostly monomer in the nanodisc. Overall, the FPLC 
chromatogram showed distinct differences between fluid and rigid nanodisc suggesting that the 
full-length DR1 assembly differs based on the composition of lipids in the membrane. All the 
nanodiscs were also analyzed by immunoblotting to identify the proteins. Nanodisc formation 
was confirmed by immunoblotting, and both MSP and full-length DR1 bands were observed in 
immunoblotting (Figure4.2F).
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Figure 4.2: Assembly of full-length DR1 differs based on the composition of lipids. Fluid 
disordered nanodisc, ratio of lipids (POPC: PSM: Cholesterol (60:1:1)): MSPE3D1: mDR1 
(1000: 10: 1) (A) FPLC chromatogram (B). Native gel (C). SDS-PAGE gel. Rigid ordered 
nanodisc, ratio of lipids (POPC: PSM: Cholesterol (1:1:1)): MSPE3D1: mDR1 (1000: 10: 1) (D). 
FPLC Chromatogram (E). SDS-PAGE gel (F). Immunoblot of various nanodiscs
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Binding of the peptide to MHCII is interrupted due to the presence of transmembrane 
region or due to the presence of lipids: For almost four decades, soluble-DR1 has been used to 
measure the binding affinity of antigenic peptides. Here we present a tool where full-length DR1 
is embedded in the synthetic membrane and available in the soluble form. We wanted to test if 
this assembly can be used for binding studies and if there is any difference between the binding 
affinity of soluble DR1 and full-length DR1 embedded in the nanodisc. For this purpose, we 
used an ELISA-based direct binding assay to measure binding affinity of biotinylated HA306-318 
(bioHA). Different concentrations of bioHA were incubated with soluble DR1, full-length DR1, 
and nanodisc to measure the binding affinity of bioHA. As shown in Figure 4.3A, 4.3B, 4.3c, 
and 4.3D, the fluorescent count for full-length DR1 and nanodisc with DR1 were less than the 
soluble DR1.
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Figure 4.3: Direct binding assay to measure the binding affinity of biotinylated HA (bioHA):
(A). soluble-DR1 (B). mDR1 (C). Empty-nanodisc (D). Fluid-nanodisc.
The difference in binding based on the lipid composition: Our ELisA-based direct binding 
assay showed low fluorescence count for the nanodisc, and we believe that it is due to inefficient 
capturing of nanodisc via antibody on the surface of the binding plate. To overcome this issue, 
we used native-gel electrophoresis to visualize the binding. To test if the peptide binds to full­
length DR1 embedded in the nanodisc, we used fluorescein-labeled HA306-318 peptide. We 
incubated the proteins with a 20-fold excess of peptide overnight at 37°C and loaded the protein 
on the native-gel. We observed that empty nanodisc also showed a fluorescent band at lower 
intensity. The presence of fluorescent band with empty nanodisc could be due to non-specific 
binding of the peptide to lipids. We measured the band intensity using imageJ and subtracted the 
empty nanodisc intensity from the samples band. We observed that simple nanodisc (1000: 10: 
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1) and fluid nanodisc showed binding which is comparable to soluble DR1 (Figure 4.4A and 
4.4B). Rigid nanodisc showed no binding with HA peptide. The non-specific binding observed 
with empty nanodisc can be explained with the buffer composition (Bockmann, Hac, Heimburg, 
& Grubmuller, 2003). We also observed a significant difference between in-band intensity when 
we used two different buffers but with the same pH (pH 7.4). We suggest that the difference in 
binding is due to variation in ionic composition of the buffer.
Taken together these results suggest that the full-length DR1 embedded in the nanodisc can be 
used as a tool to study the binding of antigenic peptides. Our preliminary results indicate that 
there is a difference in the binding based on the type of nanodisc and the buffers used during the 
binding reaction. Our initial binding assays also suggest non-specific binding with empty 
nanodisc which shows there is a need of different binding assays to study the nanodisc. In the 
future, nanodisc embedded full-length DR1 showed the potential to replace the soluble DR1 
protein.
Figure 4.4: Difference in binding due to lipid composition: (A). 5 μM protein incubated with 
100 μM of fluorescein-labeled HA peptide in PBS buffer (B). 5 μM protein incubated with 100 
μM of fluorescein-labeled HA peptide 20 mM Tris-Cl 100 mM NaCl
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Discussion
MHcII is extensively studied in its soluble form by using only the extracellular region. Studies 
have shown that the transmembrane and cytoplasmic domains of the protein play an essential 
role in the expression of MHcII as well as in B cell signaling (Harton, Jin, Hahn, & Drake, 2016; 
Harton & Bishop, 1993). However, the role of transmembrane and cytoplasmic region on the 
binding capacity of the MHcII is still unknown. There is currently no in-vitro system available, 
which can mimic the MHcII embedded in the cell membrane. The assembly of MHcII in the 
membrane also plays a vital role in the cD4+ T cell stimulation. Studies have suggested that 
MHcII can assemble in superdimers capable of triggering cD4+ T cell activation for low- 
affinity antigens (Schafer & Pierce, 1994). These superdimers show thermal and pH stability like 
heterodimer, as SDS is denatured both at a pH below 5 and temperature above 50°C (Schafer et 
al., 1998). The goal of the work reported here was to investigate how a full-length MHcII would 
incorporate in membranes and if the membrane lipid composition would affect the assembly of 
MHcII. To achieve this, we used a synthetic model membrane known as nanodiscs widely 
adopted to study membrane proteins.
First, we prepared a simple nanodisc containing only phosphatidylcholine (POPc) in the 
assembly mix. We used two different ratios of assembly mix in the preparation. We observed 
that based on the ratio of lipid, the assembly of DR1 within the nanodisc changed. For 100: 5: 1 
we found that the first fractions have nanodisc which has just superdimers while the later one 
shows dimers and superdimers both for 1000: 10: 1 assembly mix we observed superdimers and 
dimers assembled in nanodisc in first fractions and following fractions have dimers alone in the 
nanodisc. These results suggest that the percentage of lipids in the composition can alter the 
assembly of DR1 in the membrane.
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Next, we tested the membrane fluidity and phase impact on the assembly of DR1. For this, we 
prepared fluid-disordered and rigid-ordered nanodiscs by using cholesterol and sphingomyelin 
along with POPC in the assembly mix. For fluid-disordered nanodiscs, we observed one major 
peak in FPLC, and when the fractions were analyzed on native and SDS gel we found that the 
nanodisc was composed of dimers and superdimers altogether. While for rigid-ordered nanodisc 
on FPLC we observed one major peak which bifurcated at the top of the peak. The fractions on 
SDS gel show that nanodisc in the first-half peak contains superdimers with dimers while the 
later fractions have mostly dimer of DR1. These observations suggest that the fluidity and phase 
of the membrane can determine how DR1 assembles in the membrane.
Studies have shown that cholesterol-rich microdomains are associated with MHCII-peptide 
complexes at the plasma membrane of dendritic cells, and the abolishment of these cholesterol 
rich-domains reduces the activation of CD4+ T cells (Bosch et al., 2013). The clustering of 
MHCII plays an essential role in enhancing TCR signaling. In our nanodisc, we observed that 
DR1 dimers and superdimers were both present. How they arranged in the nanodisc is not 
known. But based on how clustering of the MHCII complexes is essential for T-cell activation 
we think DR1 might arrange as a cluster in the nanodiscs.
Having shown the assembly of full-length DR1 in the nanodisc, full exploitation of this tool 
requires the assessment of its peptide binding capacity. For preliminary binding studies we used 
ELISA based assay and Fam-labeled peptides. In both cases, we observed non-specific 
interactions that masked the actual binding. Through an ELISA-based assay, we noted that full­
length DR1, empty-nanodisc, and fluid-nanodisc showed comparable and lower fluorescence 
count as compared to soluble DR1. We believe the reason for the low count is maybe due to the 
inefficient capturing of the peptide-MHCII complex via L243 on the binding plates. For full­
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length DR1 we think this is possibly due to free moving transmembrane region, while for DR1 
embedded in nanodisc this is likely due to the bulky size of the nanodisc. Future approaches for 
testing the biochemical behavior of membrane embedded MHCII will include SPR and ITC. In 
our opinion, this system has the potential of mimicking the MHCII behavior as found on the 
membrane of antigen-presenting cells, and possibly revolutionizing the research field of antigen 
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The class ii MHC processing and presentation pathway is a complex process, which involves 
multiple factors influencing the selection of the antigens that are ultimately displayed to CD4+ T 
cells (Neefjes, Jongsma, paul, & Bakke, 2011). Exogenous proteins are presented via MHCii. 
The recognition of an exogenous protein is started with the uptake by antigen-presenting cells 
(ApCs) through endocytosis. The protein moves through various lysosomal compartments with 
different pH and cathepsin enzymes, which generate a pool of peptides competing for binding to 
MHCii in the MHC class ii compartment (MiiC) (Geuze, 1998). in MiiC, a newly synthesized 
MHCii molecule, or one recycle from the membrane, along with non-classical MHCii molecule 
HLA-DM, selects the peptides for presentation to CD4+ T cells (Nanda & Bikoff, 2005). There 
is more than one peptide that can bind to MHCii and presented to CD4+ T cells; among such 
peptides there are only a few that can generate significant CD4+ T cell response. peptides that 
are the focus of T cell response are known as immunodominant. immunodominant epitope 
discovery is the focus of substantial efforts due to the impact of this information on vaccine 
engineering and the understanding of the pathology of emerging pathogens or autoimmunity. 
Two models can explain how immunodominant epitopes selected via MHCii. The first model is 
a kinetic stability model, which postulates that the immunodominant epitope has intrinsic kinetic 
stability. studies have shown that immunodominant peptides have kinetic stability > 100 hours, 
and weaker epitopes have kinetic stability < 6 hours (sant et al., 2005). These epitopes are 
resistant to DM activity and weaker epitopes are also susceptible to DM activity. The second 
model is known as the “epitope accessibility” model, which proposes that immunodominant 
epitopes are easily accessible to MHCii binding sites due to their position in the protein 
structure, and they are also resistant to cathepsin activity (Kim et al., 2014; Kim & sadegh-
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Nasseri, 2015). Thus, two mechanisms can potentially determine the accessibility of the epitope 
to MHCII: “cut first and bind later” whereby a protein is first trimmed by cathepsin and then 
binds to MHCII, or “bind first and cut later” whereby a protein binds first to the MHCII and 
trimmed later at the flaming sides, whereas the MHCII itself shields intra-peptide cleavage 
sisters.
Literature shows that immunodominant epitope selection is not determined by one single factor, 
but it is dependent on multiple intertwined components. Here, we have investigated a few such 
mechanisms, namely the role of MHCII molecule biochemical behavior, the activity of DM, and 
the impact of MHCII assembly in the membrane on the selection of epitopes.
In most of our studies, we have used a set of peptides derived from H1N1 influenza 
hemagglutinin, for which a DR1-restricted immunodominance hierarchy was already established 
(Richards et al., 2007). Our first aim was to see if DM-associated IC50 can be considered a viable 
proxy of immunodominance. We measured the binding affinity of the various peptides in the 
absence and presence of DM. We observed a direct correlation between the presence of DM and 
the reduction in affinity to MHCII of those epitopes for which a weaker CD4+ T cell response 
recorded. We also tested the epitope prediction accuracy of DM-associated IC50 by plotting the 
Receiver operating characteristics (ROC) curve. When compared to different online prediction 
tools, the experimental measurement of DM-associated affinity showed better accuracy in 
predicting epitope by eliminating false-positive epitopes. The correlation between DM- 
associated IC50 and immunodominant epitope selection is novel and of certain impact in the 
field. Indeed, past and current studies focus on DM-associated half-lives instead of determining 
the role of DM during peptide binding to MHCII. We used competition binding assay to study 
the affinity of each peptide in a reaction that somewhat mimics the MIIC system, where peptides 
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of various affinity for the MHCII compete for binding in the presence of DM. We conclude that 
the DM-associated IC50 is a better correlate of immunodominance, and inclusion of this factor in 
epitope prediction tools can improve their accuracy.
Our second aim was to test the impact of pH and the length of the peptides in the MHCII 
presentation pathway. We started by looking into the role of pH in the presentation when we 
observed that immunodominant epitopes of hemagglutinin protein showed DM-susceptibility. 
Past studies have shown that immunodominant epitope kinetics is DM-resistant (Sant et al., 
2005). To reconcile the apparent paradox of experimental immunodominant peptides showing 
DM susceptibility, we started looking into the effect of pH and the length of the peptides. We 
measured the off rate of immunodominant peptides at pH 7.4 and observed greater stability in 
comparison to pH 5.4. We also tested the SDS-stability of these peptides at pH 5.4 and 7.4 and 
observed that the pH drop abolishes SDS stability of immunodominant peptides. Next, we used 
15-mer derivatives of selected immunodominant peptides and measured their kinetics at pH 5.4 
in the absence and presence of DM. These derivatives showed better stability in the absence and 
presence of DM as compared to their original longer peptides. These findings indicate that pH 
and length of the peptides can impact their kinetic stability and DM activity therein. We propose 
that these immunodominant peptides could be presented through an alternate pathway in which 
peptides bind to empty MHCII at the surface of the APCs and are recycled in shallow 
compartments. Past studies have suggested such routes of processing and presentation for 
hemagglutinin, myelin basic protein and HEK protein (Lindner & Unanue, 1996; Pinet, Vergelli, 
Martin, Bakke, & Long, 1995; Pinet & Long, 1998; Vergelli et al., 1997).
The MHCII research of the past two decades was performed by using soluble MHCII, where the 
transmembrane region of the protein is not expressed (Frayser, Sato, Xu, & Stern, 1999; Gorga, 
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Horejsi, Johnson, Raghupathy, & Strominger, 1987). Soluble MHcII is a natural choice to study 
the biochemistry and biophysics of the protein interacting with peptides. Studies have shown that 
the MHcII organization in the plasma membrane is an essential factor to trigger T-cell activation 
(Fooksman, 2014). It is not known if MHcII assembly is directly related to lipid composition. 
Thus, our third objective was to study the impact of lipid composition in the MHcII assembly. 
To this aim, we used a synthetic membrane model known as nanodisc in which the lipid 
composition is easily manipulated. We prepared different types of nanodisc with different lipids 
composition and incorporated full-length MHcII in it. We showed that, based on lipid 
composition, various oligomeric forms of MHcII assembled in the nanodiscs. In the end, we 
wanted to use the nanodisc embedded full-length MHcII as a tool to study the binding affinity of 
antigenic peptides. We have shown that this tool is not fully developed for binding study 
adopting solid-phase immunoassay steps. We believe that this difficulty is due to the orientation 
of the MHcII in the nanodisc which makes it inaccessible by the capture antibody. We also 
tested peptide-binding qualitatively using the native-gel electrophoresis, and we did observe a 
difference in binding capacity between different nanodiscs. This observation is quite interesting 
because it suggests that the orientation of the MHcII in the nanodisc dictates how the antigen 
can interact and ultimately bind. This characteristic could be reflection of what happens in the 
cells. MHcII is found on the surface of the cells, MIIc, and different endosomal compartments. 
It might be possible that the orientation of the MHcII dictates that it will bind to an antigen or 
not in that specific compartment.
Our finding addresses essential factors that can dictate the selection of immunodominant 
epitopes. Here, we showed that the inclusion of DM activity could be a crucial addition to any 
strategy aiming at predicting immunodominant epitopes. pH and cleavage susceptibility, 
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however, may impact the generation of a specific epitope and need to be considered as well. 
Finally, we show the organization of MHCII in a synthetic membrane model and the 
implications of these findings in the biophysical characterization of MHCII. This work has 
therefore led the foundation for future research aimed at deepening our understanding and 
predicting the selection of immunodominant epitopes by MHCII.
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Appendix: Fluorescence anisotropy - based analysis of the conformational modifications in
the peptide-MHCII complex structure4
4 Osan J.K, Steele H., Wang Z., Ross Alexander, Ferrante A., Kuhn T.B. Fluorescence anisotropy-based analysis of 
the conformational modifications in the peptide-MHcII structure.
This study is a preliminary study for my project. It is not completed and will be carried out in my lab in the future.
Introduction
class II major histocompatibility complex (MHcII) are glycoproteins expressed on the surface 
of antigen-presenting cells (APcs) and display antigenic peptides to cD4+ T cells (Hume, 1985). 
A MHcII molecule is synthesized in the endoplasmic reticulum (ER) usually as a nonameric 
complex, which comprises of a trimer of trimers, formed by an α and a β-chain and an invariant 
chain. This complex is transported via Golgi to MIIc-compartment where the invariant chain is 
shortened to a peptide named cLIP (class II-associated invariant chain peptide), then removed 
by a non-classical MHcII molecule HLA-DM (DM) (Ferrante, 2013). Upon cLIP release, the 
pool of antigenic peptides that are generated via cathepsin cleavage can bind to MHcII 
molecules to form MHcII-peptide complexes (pMHcII) (Neefjes, Jongsma, Paul, & Bakke, 
2011). The selected pMHcII is transported to the cell surface where they are presented to cD4+ 
T cells, which generate the immune response against the specific peptide. Among the peptide 
repertoire generated, only few of the peptides can produce a strong cD4+ T cell response, and 
these peptides are known as immunodominant peptides (Kim et al., 2014; Kim & Sadegh- 
Nasseri, 2015). Many areas of inquiry would benefit from an understanding of the factors 
determining the presentation of immunodominant peptides, such as vaccinology or 
immunopathology. Several aspects of the presentation process are usually considered to explain 
the selection of immunodominant peptides, the most relevant being pMHcII binding affinity and 
109
kinetics, structural characteristics of the complex and role of DM therein (Dai, Steede, & Landry, 
2001).
The crystal structure of several pMHCII's has shown that the peptide binds to MHCII by 
hydrophobic, ionic interaction and H-bond. There are various pockets in the MHCII binding site, 
which play an essential role in the interaction with the peptide. The major pockets are P1, P4, 
P6/P7, and P9. The numbering denotes the side chain of the peptides, which interacts with the 
binding site of MHCII. P1 is the deepest pocket at the N-terminal side of the pMHCII that 
accommodates the hydrophobic and sometimes aromatic amino acid side chain depending on the 
allele (Stern et al., 1994). Studies have shown that the region of the MHCII binding site 
including and surrounding the P1 pocket is the one undergoing the most dramatic changes upon 
complexation, in particular, the α-subunit 310 helical region and the adjacent extended strand; in 
addition, the β2 Ig-like domain, and the pronounced kink in the β-subunit helical region (β62-71) 
appear to be structurally labile as well (Pos et al., 2012; Rupp et al., 2011; Schulze, Anders, 
Sethi, & Call, 2013).
Another important factor in the selection of immunodominant epitopes is the activity of DM. The 
role of DM is not only limited to the removal of CLIP, but it also plays an essential role in the 
selection of kinetically stable pMHCII. Studies have shown that DM accelerates the exchange of 
the peptides and generates the pMHCII, which are kinetically stable. Recent reports have shown 
that two main factors play an essential role in determining DM susceptibility. One factor is 
occupancy of the P1 pocket, and the second factor is the overall conformational modification in 
the MHCII as it interacts with the peptide (Pos et al., 2012; Yin & Stern, 2013).
In this study, we aimed to analyze changes in MHCII structural conformation upon the binding 
of the peptide in the absence and presence of DM. For this purpose, we generated two separate 
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single-cysteine mutations in the α-subunit 310 helical region and one in the β-subunit helical 
region. We used fluorescence anisotropy to measure the anisotropy of the pMHCII complex in 
the absence and presence of the DM. We used HA306-318 from H3 subtype of influenza and 
HA440-455 and HA323-340 from H1N1 influenza to form pMHCII complexes. Our preliminary 
data showed that the anisotropy change is dependent on the function of the bound peptide. We 
also observed that for peptide with stronger CD4+ T cell response there was less change in 
anisotropy when incubated with DM as compare to peptide with lower CD4+ T cell response. 
Initially we observed that there was inconsistency between three repeats. Upon performing three 
more repeats with our samples, we found similar inconsistency. This result suggested that it is 
possible that the fluorescein dye is binding non-specifically to our protein. Further mass 
spectrometry analysis of our labeled protein confirmed that the dye is binding non-specifically to 
our protein. This makes it very difficult to analyze our data as it is difficult to tell how much 
anisotropy is contributed by non-specific labeling v/s specific labeling. Our preliminary results 
suggested that anisotropy studies can reveal the mechanism behind DM activity. Future work 
should focus on labeling of the protein and repeating anisotropy experiments to provide valuable 
information needed to understand how DM screen different peptides for antigen presentation.
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Materials and methods:
DR1 mutant proteins for fluorescence anisotropy: For fluorescent labeling of DR1, cysteine 
mutations were introduced at specific positions of the α and the β-chains thus producing three 
cysteine mutants: α45-DR1, α52-DR1, and β65-DR1. Here the number denotes the position of 
the amino acid which is substituted to cysteine, and the symbol indicates the chain of DR1 
protein. Genscript inc prepared plasmid for these mutants. s2 Drosophila melanogaster cell line 
was transfected using calcium phosphate transfection kit, and hygromycin was used as a 
selection agent. The cells were induced using copper sulfate at a concentration of 500 μM. 
soluble protein were purified by using protein A sepharose beads, which cross-linked with the 
L243 antibody. The mutant protein was confirmed by mass spectrometry analysis performed at 
University of Montana, Bozeman. Wild-type DR1 (WT DR1) was expressed in our lab in s2 
Drosophila melanogaster cell line and purified by using L243 affinity column chromatography 
(stern et al., 1994).
Peptides synthesis: Four peptides were selected for the fluorescence anisotropy measurement. 
peptide HA306-318 (GpKYVKQNTLKLAT) from influenza A virus H3 subtype was selected as a 
benchmark peptide due to past structural studies with this peptide. We also selected two peptides 
derived from the hemagglutinin protein of the H1N1 influenza virus for which CD4+ T cell 
response was already known. We used HA440-455 (peptide 440) and HA323-340 (peptide 47) 
with two different types of CD4+ T cell responses, where HA440-455 showed strong CD4+ T 
cell response and HA323-340 low CD4+ T cell response in the ELispOT assay performed by 
sant et al (Richards et al., 2007). These peptides were synthesized by ABi scientific using Fmoc 
chemistry and fully automated multiple peptide synthesizer.
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Fluorescence anisotropy: DR1 (WT and mutants) were labeled with fluorescein-5-maleimide at 
room temperature for three hours. Free dye was removed by washing with 20 mM PBS buffer 
ten times using Centricon-30 spin filters. 5 μM labeled proteins incubated with a 10-fold excess 
of unlabeled peptide overnight at 37C to generate the peptide-MHCII (pMHCII) complexes. The 
complexes were analyzed on the fluorimeter available in Dr. Alexander Ross lab at the 
University of Montana, Missoula, to measure the anisotropy of each complex. The overview of 
the fluorimeter shown in figure 1.
Mass spectrometry analysis: Specific and non-specific labeling were analyzed by mass 
spectrometry. Unlabeled WT and mutant DR1 along with fluorescent labeled DR1 were sent to 
Colorado State University. Samples were analyzed on MALDI-TOF to calculate the mass to 
charge ratio for each sample.
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Figure 1. Scheme of Fluorimeter setup for the dynamic anisotropy measurement
Results:
Anisotropy measurement for pMHCII complexes: In this study, we wanted to understand 
which residues of the MHCII molecules are involved during the binding of the peptides and if 
there is a change in the molecular environment when DM is around. Thus, we designed three 
cysteine DR1 mutants for this purpose. Each mutant has a single cysteine mutation at a specific 
residue which was neighbor to the α-subunit 310 helical region and the β-subunit helical region 
(β62-71). Previous studies have shown that these regions upon binding to the peptides showed 
changes in confirmation (Painter, Cruz, Lopez, Stern, & Zavala-Ruiz, 2008; Pos et al., 2012). We 
created mutations at positions 45 and 52 of α-chain and position 65 of β-chain. After mutation 
was created, the samples were sent to University of Montana, Bozeman for mass spectrometry 
analysis to confirm cysteine mutation. Three peptides HA306-318 (H3 influenza subtype), HA440- 
455 and HA323-340 (H1N1 influenza) were selected for our anisotropy experiment. The 
fluorescence anisotropy measurement was performed at University of Montana, Missoula in Dr. 
Alexander Ross lab. First, we labeled WT and mutant DR1 with fluorescein-5-maleimide. WT 
DR1 was used as a control since it has a free cysteine which can be labeled with fluorescein. 
After labeling with fluorescein dye, 5 μM labeled DR1 proteins were incubated with 10-fold 
excess of peptide overnight. The pMHCII complexes were analyzed on the fluorometer. The 
anisotropy was measured for complexes in the absence and presence of DM. We calculated the 
mean of the steady-state anisotropy (Table 1). When we calculated the change in the anisotropy 
after addition of DM, we observed that for peptide 47 the anisotropy decrease was more as 
compared to other peptides (as shown in Figure 1). These show that the MHCII-peptide 47 
complex might be more flexible in the presence of DM as compared to the other peptides.
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Table 1: Steady-state anisotropy measurement for pMHCII complexes in the absence and 
presence of DM: Anisotropy was measured for complexes made with α45 DR1, α52 DR1, and 
β65 DR1. For each constant value mean of repeats were calculated.
Protein name Peptide used 
for complex








DR1 None No 0.073 0.005
α-45 DR1 None No 0.172 0.030
α-52 DR1 None No 0.180 0.027
β-65 DR1 None No 0.161 0.041
DR1 HA306-318 No 0.166 0.037
HA306-318 Yes 0 0.175 0.043
HA306-318 Yes 24 0.163 0.059
α-45 DR1 HA306-318 No 0.194 0.020
HA306-318 Yes 0 0.205 0.030
HA306-318 Yes 24 0.185 0.023
α-52 DR1 HA306-318 No 0.154 0.044
HA306-318 Yes 0 0.168 0.040
HA306-318 Yes 24 0.190 0.015
β-65 DR1 HA306-318 No 0.203 0.012
HA306-318 Yes 0 0.190 0.016
HA306-318 Yes 24 0.183 0.011
α-45 DR1 440 No 0.183 0.12
440 Yes 0 0.198 0.012
440 Yes 24 0.183 0.022
α-52 DR1 440 No 0.191 0.015
440 Yes 0 0.191 0.005
440 Yes 24 0.172 0.041
β-65 DR1 440 No 0.207 0.016
440 Yes 0 0.192 0.016
440 Yes 24 0.184 0.016
α-45 DR1 47 No 0.201 0.021
47 Yes 0 0.200 0.007
47 Yes 24 0.166 0.039
α-52 DR1 47 No 0.204 0.011
47 Yes 0 0.196 0.009
47 Yes 24 0.152 0.030
β-65 DR1 47 No 0.201 0.012
47 Yes 0 0.175 0.050
47 Yes 24 0.184 0.011
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Figure 2: Change in the steady-state anisotropy after addition of DM
Mass spectrometry analysis to quantify the amount of fluorescein bound to MHCII protein 
specifically or non-specifically: Our preliminary analysis of fluorescence anisotropy 
measurement showed a discrepancy between the repeats. Upon increasing our repeat runs from 
three to six we still observed the same problem. We thought that the difference between repeats 
might be due to unspecific binding of the fluorescein dye to our protein. To verify this, we sent 
the unlabeled proteins along with labeled proteins to the mass spectrometry facility of Colorado 
State University. The proteins were analyzed using MALDI-TOF. The results showed that there 
was no difference in the mass to charge ratio between unlabeled and labeled protein (data not 
shown). Based on this result we concluded that there is a possibility that there is no covalently 
attached dye portion of the protein flew during the measurement because the amount of labeled 
protein is too low as compare to unlabeled protein. These results support our theory that the 
inconsistency between the repeats might be due to the unspecific labeling of the fluorescein dye 
to the MHCII protein. Due to the amount of unknown unspecific label dye it is difficult to know 
how much anisotropy contribution is from the unspecific labeling and how much is from labeled 
protein.
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Conclusion and future directions:
MHCII molecule presents antigenic peptides to CD4+ T cells to generate the immune response 
against specific pathogens. It is shown that the non-classical MHCII molecule DM plays an 
essential role in generating kinetically stable pMHCII complexes which are presented to CD4+ T 
cells. Here, we wanted to understand the structural component of MHCII which is involved with 
DM to select the peptides which are presented to CD4+ T cells. To understand how the 
molecular environment of pMHCII complex changed in the presence of DM, we generated single 
cysteine DR1 mutant. The cysteine mutation is in that region of α and β-chain of MHCII, which 
are known to change during the binding of a peptide to MHCII molecule. We labeled the 
cysteine molecule with fluorescein-5-maleimide and incubated the labeled protein with different 
peptides for which the CD4+ T cell response is already known. We measured the steady-state 
anisotropy for each pMHCII complexes in the absence and presence of DM by using fluorimeter. 
Our preliminary data showed that the change due to the presence of DM was more imminent in 
the peptide 47 which has a lower CD4+ T cell response as compared to other peptides. Increased 
experimental replicates lead to inconsistency between the repeats. Mass spectrometry analysis 
showed that there is no difference in the mass between unlabeled and labeled proteins. This can 
be due to the lack of efficient labelling of dye to our protein and there being more amount of dye 
sticking non-specifically to our protein. These results raise a reasonable doubt on our collected 
data as it makes it difficult to separate the anisotropy associated with specific and non-specific 
labeling. Since our preliminary studies indicate that there might be a difference in anisotropy 
based on the flexibility of the complex, and DM susceptibility may be dependent on the 
structural change of pMHCII complexes, we believe a detail structural studies of pMHCII 
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